<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="iso-abbrev">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="publisher-id">OMCL</journal-id><journal-title-group><journal-title>Oxidative Medicine and Cellular Longevity</journal-title></journal-title-group><issn pub-type="ppub">1942-0900</issn><issn pub-type="epub">1942-0994</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7603620</article-id><article-id pub-id-type="doi">10.1155/2020/1602816</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>
<italic>Irvingia gabonensis</italic> Seed Extract: An Effective Attenuator of Doxorubicin-Mediated Cardiotoxicity in Wistar Rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Olorundare</surname><given-names>Olufunke</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1314-6282</contrib-id><name><surname>Adeneye</surname><given-names>Adejuwon</given-names></name><email>adeneye2001@yahoo.com</email><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Akinsola</surname><given-names>Akinyele</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kolo</surname><given-names>Phillip</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Agede</surname><given-names>Olalekan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Soyemi</surname><given-names>Sunday</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mgbehoma</surname><given-names>Alban</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Okoye</surname><given-names>Ikechukwu</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Albrecht</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5358-077X</contrib-id><name><surname>Mukhtar</surname><given-names>Hasan</given-names></name><xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Health Sciences, University of Ilorin, Ilorin, Kwara State, Nigeria</aff><aff id="I2">
<sup>2</sup>Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Clinical Sciences, Lagos State University College of Medicine, 1-5 Oba Akinjobi Way, G.R.A., Ikeja, Lagos State, Nigeria</aff><aff id="I3">
<sup>3</sup>Department of Medicine, Faculty of Clinical, College of Health Sciences, University of Ilorin, Ilorin, Kwara State, Nigeria</aff><aff id="I4">
<sup>4</sup>Department of Pathology and Forensic Medicine, Faculty of Basic Clinical Sciences, Lagos State University College of Medicine, 1-5 Oba Akinjobi Way, G.R.A., Ikeja, Lagos State, Nigeria</aff><aff id="I5">
<sup>5</sup>Department of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, 1-5 Oba Akinjobi Way, G.R.A., Ikeja, Lagos State, Nigeria</aff><aff id="I6">
<sup>6</sup>Department of Oral Pathology and Medicine, Faculty of Dentistry, Lagos State University College of Medicine, 1-5 Oba Akinjobi Way, G.R.A., Ikeja, Lagos State, Nigeria</aff><aff id="I7">
<sup>7</sup>Department of Animal Sciences, 1675 Observatory Drive, University of Wisconsin, Madison, WI 53706, USA</aff><aff id="I8">
<sup>8</sup>Department of Dermatology, University of Wisconsin, Madison, Medical Science Center, 1300 University Avenue, Madison, WI 53706, USA</aff><author-notes><fn fn-type="other"><p>Academic Editor: Patricia Morales</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>10</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>1602816</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>8</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>5</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Olufunke Olorundare et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Cardiotoxicity as an off-target effect of doxorubicin therapy is a major limiting factor for its clinical use as a choice cytotoxic agent. Seeds of <italic>Irvingia gabonensis</italic> have been reported to possess both nutritional and medicinal values which include antidiabetic, weight losing, antihyperlipidemic, and antioxidative effects. Protective effects of <italic>Irvingia gabonensis</italic> ethanol seed extract (<italic>IGESE</italic>) was investigated in doxorubicin (DOX)-mediated cardiotoxicity induced with single intraperitoneal injection of 15&#x02009;mg/kg of DOX following the oral pretreatments of Wistar rats with 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> for 10 days, using serum cardiac enzyme markers (cardiac troponin I (cTI) and lactate dehydrogenase (LDH)), cardiac tissue oxidative stress markers (catalase (CAT), malonyldialdehyde (MDA), superoxide dismutase (SOD), glutathione-S-transferase (GST), glutathione peroxidase (GSH-Px), and reduced glutathione (GSH)), and cardiac histopathology endpoints. In addition, both qualitative and quantitative analyses to determine IGESE's secondary metabolites profile and its <italic>in vitro</italic> antioxidant activities were also conducted. Results revealed that serum cTnI and LDH were significantly elevated by the DOX treatment. Similarly, activities of tissue SOD, CAT, GST, and GSH levels were profoundly reduced, while GPx activity and MDA levels were profoundly increased by DOX treatment. These biochemical changes were associated with microthrombi formation in the DOX-treated cardiac tissues on histological examination. However, oral pretreatments with 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> dissolved in 5% DMSO in distilled water significantly attenuated increases in the serum cTnI and LDH, prevented significant alterations in the serum lipid profile and the tissue activities and levels of oxidative stress markers while improving cardiovascular disease risk indices and DOX-induced histopathological lesions. The <italic>in vitro</italic> antioxidant studies showed <italic>IGESE</italic> to have good antioxidant profile and contained 56 major secondary metabolites prominent among which are <italic>&#x003b3;</italic>-sitosterol, Phytol, neophytadiene, stigmasterol, vitamin E, hexadecanoic acid and its ethyl ester, Phytyl palmitate, campesterol, lupeol, and squalene. Overall, both the <italic>in vitro</italic> and <italic>in vivo</italic> findings indicate that <italic>IGESE</italic> may be a promising prophylactic cardioprotective agent against DOX-induced cardiotoxicity, at least in part mediated via <italic>IGESE</italic>'s antioxidant and free radical scavenging and antithrombotic mechanisms.</p></abstract><funding-group><award-group><funding-source>Tertiary Education Trust Fund</funding-source><award-id>TETFUND/NRF/UIL/ILORIN/STI/VOL.1/B2.20.12</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Doxorubicin (otherwise known as Adriamycin) is one of the antibiotic cytotoxic agent belonging to the anthracycline class of anticancer agents [<xref rid="B1" ref-type="bibr">1</xref>]. Doxorubicin is known to bind to and intercalate with DNA, thereby inhibiting the resealing action of topoisomerase II during normal DNA replication needed for cancer cell division and growth [<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Doxorubicin is often used in clinical setting in combination with other classes of anticancer agents as &#x0201c;chemo cocktail&#x0201d; in the management of various types of solid and blood cancers such as breast and ovarian, leukemia (acute myelogenous leukemia (AML) and acute lymphoblastic leukemia), Hodgkin lymphoma, non-Hodgkin lymphoma, Wilm's tumor, neuroblastoma, and sarcoma [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. For example, for breast cancer management, doxorubicin is typically combined and given with cyclophosphamide; for lymphomas and leukemias, it is combined with other cytotoxic agents to make regimens like CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) [<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>]. However, the clinical use of doxorubicin have been reported to be associated with major common side effects such as pain at the injection site, anorexia, fever, nausea and vomiting, stomatitis, dyspnea, nose bleeding, alopecia, immunosuppression, weight gain, hepatic and renal injuries, and severe cardiotoxicity [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B13" ref-type="bibr">13</xref>], while its occasional side effects include hyperuricemia, heart failure, pericardial effusion, cardiomyopathy, conjunctivitis, and skin rashes [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. Of these side effects, cumulative and dose-related cardiomyopathy and heart failure are of grave concerns to cancer patients and managing physicians alike, thus, limiting its clinical use [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>]. Although the pathogenesis of doxorubicin-induced cardiotoxicity has been reported to be complex and fuzzy, the pivotal role of iron-mediated formation of reactive oxygen species (ROS) cannot be underscored [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>In preventing the development of doxorubicin-induced cardiotoxicity, chemocurative and chemopreventive strategies involving the use of flavonoids, especially monoHER, have been advocated [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. MonoHER has been reported to elicit potent antioxidant, iron chelating, and carbonyl reductase inhibiting effects while still protecting the antitumor activity of anthracycline anticancer agents [<xref rid="B22" ref-type="bibr">22</xref>]. Similarly, the effectiveness of dexrazoxane (an iron chelating agent) [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B23" ref-type="bibr">23</xref>], dextromethionine [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>], and angiotensin-converting enzyme inhibitors&#x02014;zofenopril and lisinopril [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>]&#x02014;in ameliorating doxorubicin-related cardiotoxicity have also been reported. These agents, especially dexrazoxane, are known to mitigate oxidative stress by chelating iron and catalytically inhibiting topoisomerase II, thus preventing doxorubicin-induced double strand DNA breaks [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. However, these chemopreventive agents are expensive and not readily accessible to patients, therefore, necessitating the need for the discovery and development of more effective but cheaper and more readily accessible alternatives especially ones of medicinal plant origin. One of these is the <italic>Irvingia gabonensis</italic> seed extract.</p><p>
<italic>Irvingia gabonensis</italic> (Aubry-Le Comte ex O'Rorke) Bail belonging to the family, Irvingiaceae, is known as African Mango (in English). Its other common names include bread tree, African wild mango, wild mango, and bush mango [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>], and its local names include <italic>Apon</italic> (in Yoruba, Southwest Nigeria), <italic>Ogbono</italic> (in Igbo, Southeast Nigeria), and <italic>Goron</italic> or <italic>biri</italic> (in Hausa, Northern Nigeria) [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. <italic>Irvingia gabonensis</italic> is widely cultivated in West African countries including southwest and southeast Nigeria, southern Cameroon, C&#x000f4;te d'Ivoire, Ghana, Togo, and Benin, to produce its edible fruit whose seed is used in the preparation of local delicious viscous soup for swallowing yam and cassava puddings [<xref rid="B34" ref-type="bibr">34</xref>]. Fat extracted from its seeds is commonly known as dika fat and majorly consists of C12 and C14 fatty acids, alongside with smaller quantities of C10, C16, and C18, glycerides and proteins [<xref rid="B34" ref-type="bibr">34</xref>]. <italic>Irvingia gabonensis</italic> seeds are also a good source of nutrients including a variety of vitamins and minerals such as sodium, calcium, magnesium, phosphorus, and iron. It is also a rich source of flavonoids (quercetin and kaempferol), ellagic acid, mono-, di-, and tri-O-methyl-ellagic acids, and their glycosides which are potent antioxidants [<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>].</p><p>Phytochemical analysis of its seeds showed that it contains tannins, alkaloids, flavonoids, cardiac glycosides, steroids, carbohydrate, volatile oils, and terpenoids [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>] and its proximate composition of moisture 1.4 &#x000b1; 0.11%, ash 6.8 &#x000b1; 0.12%, crude lipid 7.9 &#x000b1; 0.01%, crude fiber 21.6 &#x000b1; 0.45%, and crude protein 5.6 &#x000b1; 0.20% [<xref rid="B33" ref-type="bibr">33</xref>]. Pure compounds already isolated from the seed extract of include: methyl 2-[2-formyl-5-(hydroxymethyl)-1 H-pyrrol1yl]-propanoate, kaempferol-3-0-<italic>&#x003b2;</italic>-D-6<sup>&#x02033;</sup> (p-coumaroyl) glucopyranoside and lupeol (3<italic>&#x003b2;</italic>-lup-20(29)-en-3-ol). Erstwhile, the antioxidant property of <italic>Irvingia gabonensis</italic> seed extract has been largely attributed to its high lupeol content [<xref rid="B39" ref-type="bibr">39</xref>].</p><p>In view of the above, the current study was designed at evaluating the possible protective effect of the crude non-defatted ethanol seed extract of <italic>Irvingia gabonensis</italic> against doxorubicin-mediated cardiotoxicity in rats using cardiac injury markers, oxidative stress markers, and histopathology results as endpoint outcomes.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Extraction Process and Calculation of Percentage Yield</title><p>For <italic>Irvingia gabonensis</italic> seed extraction, 3&#x02009;kg of pulverized <italic>Irvingia gabonensis</italic> dried seeds was macerated in 12&#x02009;L of absolute ethanol for 72 hours after which it was continuously stirred for 1 hour before it was filtered using 180&#x02009;mm of filter paper. The filtrate was then concentrated at 40&#x000b0;C to complete dryness using rotary evaporator. The dark-colored, oily paste-like residue left behind was weighed, stored in air- and water-proof container which was kept in a refrigerator at 4&#x000b0;C. This extraction process was repeated for two more times. From the stock, fresh solutions were made whenever required.</p><p>% yield was calculated as {weight&#x02009;of&#x02009;crude&#x02009;extract&#x02009;obtained&#x02009;(g) &#x000f7; weight&#x02009;of&#x02009;pulverized&#x02009;dry&#x02009;seed&#x02009;extracted&#x02009;(g)} &#x000d7; 100.</p></sec><sec id="sec2.2"><title>2.2. Preliminary Qualitative Phytochemical Analysis of IGESE</title><p>The presence of saponins, tannins, alkaloids, flavonoids, anthraquinones, glycosides, and reducing sugars in <italic>IGESE</italic> was detected by the simple and standard qualitative methods described by Trease and Evans [<xref rid="B40" ref-type="bibr">40</xref>] and Sofowora [<xref rid="B41" ref-type="bibr">41</xref>].</p></sec><sec id="sec2.3"><title>2.3. Preliminary Quantitative Determination of Secondary Metabolites in and Phytoscan of IGESE</title><p>Preliminary quantitative analysis of the secondary metabolites (including phenol, flavonoids, tannin, terpenoids, steroids, reducing sugars, saponin, and phlobatannin) in <italic>IGESE</italic> was done using methods earlier described by Olorundare et al. [<xref rid="B42" ref-type="bibr">42</xref>]. Similarly, using gas chromatography-mass spectrophotometer (GC-MS) for phytoscan, the relative abundance of the secondary metabolites in <italic>IGESE</italic> was done using the procedures earlier described by Olorundare et al. [<xref rid="B42" ref-type="bibr">42</xref>].</p></sec><sec id="sec2.4"><title>2.4. In Vitro Antioxidant Studies of IGESE</title><p>DPPH scavenging activity, FRAP, and nitric oxide scavenging activities of <italic>IGESE</italic> were determined using the procedures earlier described by Olorundare et al. [<xref rid="B42" ref-type="bibr">42</xref>].</p></sec><sec id="sec2.5"><title>2.5. Experimental Animals</title><p>Young adult male Wistar Albino rats (aged 8-10 weeks old and body weight: 140-160&#x02009;g) used in this study were obtained from the Animal House of the Lagos State University College of Medicine, Ikeja, Lagos State, Nigeria, after an ethical approval (UERC Approval number: UERC/ASN/2020/2022) was obtained from the University of Ilorin Ethical Review Committee for Postgraduate Research. The rats were handled in accordance with international principles guiding the Use and Handling of Experimental Animals [<xref rid="B43" ref-type="bibr">43</xref>]. The rats were maintained on standard rat feed (Ladokun Feeds, Ibadan, Oyo State, Nigeria) and potable water which were made available <italic>ad libitum</italic>. The rats were maintained at an ambient temperature between 28 and 30&#x000b0;C, humidity of 55 &#x000b1; 5%, and standard (natural) photoperiod of approximately 12/12 hours of alternating light and dark periodicity.</p></sec><sec id="sec2.6"><title>2.6. Measurement of Body Weight</title><p>The rat body weights were taken at the beginning and last of the experiment using a digital rodent weighing scale (&#x000ae;Virgo Electronic Compact Scale, New Delhi, India). The obtained values were expressed in grams (g).</p></sec><sec id="sec2.7"><title>2.7. Induction of DOX-Induced Cardiotoxicity and Treatment of Rats</title><p>Prior to commencement of the experiment, rats were randomly allotted into 7 groups of 7 rats per group such that the weight difference between and within groups was not more than &#x000b1;20% of the average weight of the sample population of rats used for the study. However, the choice of the therapeutic dose range of 100, 200, and 400&#x02009;mg/kg/day of <italic>IGESE</italic> was made based on the result of the orientation studies conducted.</p><p>Treatments of rats with distilled water, 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> in 5% DMSO distilled water, 20&#x02009;mg/kg/day of vitamin C (standard antioxidant drug) for 10 days, and subsequent treatment with single intraperitoneal dose (15&#x02009;mg/kg) doxorubicin in 0.9% normal saline on day 11 are as indicated in <xref rid="tab1" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2.8"><title>2.8. Collection of Blood Samples</title><p>72 hours postdoxorubicin injection, overnight fasted rats were humanely sacrificed under light inhaled diethyl ether anesthesia, and whole blood samples were collected directly from the heart with fine 21G injectable needle and 5&#x02009;ml syringe without causing damage to the heart tissues. The rat heart, liver, kidneys, and testes were carefully identified, harvested, and weighed.</p></sec><sec id="sec2.9"><title>2.9. Bioassays</title><p>Blood samples collected into 10&#x02009;ml plain sample bottles were allowed to clot at room temperature for 6 hours and then centrifuged at 5000&#x02009;rpm to separate clear sera from the clotted blood samples. The clear samples were obtained for assays of the following biochemical parameters: serum cardiac troponin I, LDH, TG, TC, and cholesterol fractions (HDL-c, LDL-c) using estimated standard bioassay procedures and commercial kits.</p></sec><sec id="sec2.10"><title>2.10. AI and CRI Calculation</title><p>AI was calculated as LDL &#x02212; c&#x02009;(mg/dl) &#x000f7; HDL &#x02212; c&#x02009;(mg/dl) [<xref rid="B44" ref-type="bibr">44</xref>], while CRI was calculated as TC&#x02009;(mg/dl) &#x000f7; HDL &#x02212; c&#x02009;(mg/dl) [<xref rid="B45" ref-type="bibr">45</xref>].</p></sec><sec id="sec2.11"><title>2.11. Determination of Cardiac Tissue Antioxidant Profile</title><p>After the rats were sacrificed humanely under inhaled diethyl ether, the heart was harvested <italic>en bloc</italic>. The heart was gently and carefully divided into two halves (each consisting of the atrium and ventricle) using a new surgical blade. The left half of the heart was briskly rinsed in ice-cold 1.15% KCl solution in order to preserve the oxidative enzyme activities of the heart before being placed in a clean sample bottle which itself was in an ice-pack filled cooler. This is to prevent the breakdown of the oxidative stress enzymes in these organs.</p><p>Activities of cardiac tissue oxidative stress markers such as SOD, CAT, MAD, GSH, GPx, and GST were assays using methods earlier described by Olorundare et al. [<xref rid="B42" ref-type="bibr">42</xref>].</p></sec><sec id="sec2.12"><title>2.12. Histopathological Studies</title><p>The right halves of the seven randomly selected rats from each treatment and control groups were subjected to histopathological examinations; the choice of the right ventricle was based on its reported most susceptibility to doxorubicin toxicity of the four heart chambers. The dissected right heart half was briskly rinsed in normal saline and then preserved in 10% formo-saline. It was then completely dehydrated in 100% ethanol before it was embedded in routine paraffin blocks. 4-5&#x02009;<italic>&#x003bc;</italic>m thick sections of the cardiac tissue were prepared from these paraffin blocks and stained with hematoxylin-eosin. These were examined under a photomicroscope connected to a host computer for any associated histopathological lesions.</p></sec><sec id="sec2.13"><title>2.13. Statistical Analysis</title><p>Data were presented as mean &#x000b1; S.E.M. of four observations for the <italic>in vitro</italic> studies and mean &#x000b1; S.D. of seven observations for the <italic>in vivo</italic> studies, respectively. Statistical analysis was done using a two-way analysis of variance followed by the Student-Newman-Keuls test on GraphPad Prism Version 5. Statistical significance was considered at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. % Yield</title><p>Complete extraction of <italic>Irvingia gabonensis</italic> ethanol seed extract in absolute ethanol resulted in an average yield of 4.31%, which was a very dark brown, oily, and sweet-smelling paste-like residue that was soluble in methanol and ethanol but not in water.</p></sec><sec id="sec3.2"><title>3.2. Preliminary Qualitative Phytochemical Analysis of IGESE</title><p>This shows the presence of phenol, flavonoids, tannin, terpenoids, steroids, and reducing sugars, while saponin and phlobatannin were absent.</p></sec><sec id="sec3.3"><title>3.3. Preliminary Quantification of the Secondary Metabolites in IGESE</title><p>Preliminary quantitative analysis of <italic>IGESE</italic> showing the relative abundance and quantification of secondary metabolites (expressed in mg/100&#x02009;g of dry <italic>IGESE</italic>) shows the presence of phenol (57.18 &#x000b1; 0.05), flavonoids (18.19 &#x000b1; 0.07), alkaloids (50.51 &#x000b1; 0.17), steroids (47.47 &#x000b1; 0.03), tannin (41.60 &#x000b1; 0.03), and reducing sugars (65.64 &#x000b1; 0.23) (<xref rid="tab2" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3.4"><title>3.4. Phytoscan for Secondary Metabolites in IGESE Using Gas Chromatography-Mass Spectrometry</title><p>The presence and relative abundance of fifty-six (56) major secondary metabolites in <italic>IGESE</italic> obtained through gas chromatography-mass spectrometry and phytoscan based on CAS Library search included 4,6-di-O-methyl-alpha-d-galactose (27.08%), <italic>n</italic>-hexadecanoic acid (5.51%), undecanoic acid (5.08%), 9,12,15-octadecatrienoic acid, (Z,Z,Z) (4.84%), <italic>&#x003b3;</italic>-sitosterol (4.18%), Phytol (3.84%), neophytadiene (3.77%), ethyl 9,12,15-octadecatrienoate (3.65%), stigmasterol (3.03%), vitamin E (2.91%), hexadecanoic acid, ethyl ester (2.51%), Phytyl palmitate (1.92%), campesterol (1.34%), lupeol (1.22%), 9,12-octadecadienoic acid (Z,Z) (0.96%), octadecanoic acid, ethyl ester (0.91%), lup-20(29)-en-3-one (0.84%), <italic>&#x003b2;</italic>-amyrone (0.82%), phenol (0.82%), 1-hexacosanol (0.77%), pyrrolidine, 1-(1-cyclohexen-1-yl)-(0.71%), triacontyl acetate (0.66%), octadecanoic acid, 2,3-dihydroxypropyl ester (0.59%), <italic>&#x003b3;</italic>-tocopherol (0.35%), 1,2-bis(trimethylsilyl) benzene (0.34%), and squalene (0.26%) (<xref rid="tab3" ref-type="table">Table 3</xref> and <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="sec3.5"><title>3.5. <italic>In Vitro</italic> Antioxidant Profiling of IGESE</title><sec id="sec3.5.1"><title>3.5.1. Determination of DPPH Scavenging Activity of <italic>IGESE</italic></title><p>
<xref rid="tab4" ref-type="table">Table 4</xref> shows the <italic>in vitro</italic> DPPH scavenging activities of 25&#x02009;<italic>&#x003bc;</italic>g/ml, 50&#x02009;<italic>&#x003bc;</italic>g/ml, 75&#x02009;<italic>&#x003bc;</italic>g/ml, and 100&#x02009;<italic>&#x003bc;</italic>g/ml of <italic>IGESE</italic> in comparison with those of corresponding doses of the standard antioxidant drug (Vit. C) used. <italic>IGESE</italic>'s DPPH scavenging activities were significantly (<italic>p</italic> &#x0003c; 0.001 and <italic>p</italic> &#x0003c; 0.0001) dose related at 75&#x02009;<italic>&#x003bc;</italic>g/ml and 100&#x02009;<italic>&#x003bc;</italic>g/ml, and these were comparable to that of Vit. C (<xref rid="tab4" ref-type="table">Table 4</xref>).</p></sec><sec id="sec3.5.2"><title>3.5.2. Determination of NO Scavenging Activity of <italic>IGESE</italic></title><p>
<xref rid="tab5" ref-type="table">Table 5</xref> shows the <italic>in vitro</italic> NO scavenging activities of 25&#x02009;<italic>&#x003bc;</italic>g/ml, 50&#x02009;<italic>&#x003bc;</italic>g/ml, 75&#x02009;<italic>&#x003bc;</italic>g/ml, and 100&#x02009;<italic>&#x003bc;</italic>g/ml of <italic>IGESE</italic> in comparison with those of corresponding doses of the standard antioxidant drug (Vit. C). <italic>IGESE</italic>'s NO scavenging activities of the extract were significantly (<italic>p</italic> &#x0003c; 0.001, <italic>p</italic> &#x0003c; 0.0001) dose related and comparable to that of Vit. C at 75&#x02009;<italic>&#x003bc;</italic>g/ml and 100&#x02009;<italic>&#x003bc;</italic>g/ml of <italic>IGESE</italic> (<xref rid="tab5" ref-type="table">Table 5</xref>).</p></sec><sec id="sec3.5.3"><title>3.5.3. Determination of FRAP of <italic>IGESE</italic></title><p>
<xref rid="tab6" ref-type="table">Table 6</xref> shows <italic>IGESE</italic>'s <italic>in vitro</italic> ferric reducing activity power of 25&#x02009;<italic>&#x003bc;</italic>g/ml, 50&#x02009;<italic>&#x003bc;</italic>g/ml, 75&#x02009;<italic>&#x003bc;</italic>g/ml, and 100&#x02009;<italic>&#x003bc;</italic>g/ml in comparison with those of corresponding doses of the standard antioxidant drug. Again, <italic>IGESE</italic>'s FRAP activities were significantly (<italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, <italic>p</italic> &#x0003c; 0.0001) dose dependent and comparable to that of Vit. C especially at 50&#x02009;<italic>&#x003bc;</italic>g/ml, 75&#x02009;<italic>&#x003bc;</italic>g/ml, and 100&#x02009;<italic>&#x003bc;</italic>g/ml of <italic>IGESE</italic> (<xref rid="tab6" ref-type="table">Table 6</xref>).</p></sec></sec><sec id="sec3.6"><title>3.6. Effect of IGESE on the Cardiac Tissue Oxidative Stress Markers (GSH, GST, GPx, SOD, CAT, and MDA) of DOX-Treated Rats</title><p>Intraperitoneal injection of DOX to rats resulted in significant (<italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001) decreased activities of SOD, CAT, GPx, GST, and GSH levels while significantly increasing (<italic>p</italic> &#x0003c; 0.001) MDA activities (<xref rid="tab7" ref-type="table">Table 7</xref>). However, oral pretreatment with <italic>IGESE</italic> significantly (<italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001) attenuated the alterations in the activities of these cardiac tissue enzyme markers. Similarly, <italic>IGESE</italic> pretreatment significantly (<italic>p</italic> &#x0003c; 0.001 and <italic>p</italic> &#x0003c; 0.0001) and dose dependently reduced MDA levels (<xref rid="tab7" ref-type="table">Table 7</xref>).</p></sec><sec id="sec3.7"><title>3.7. Effect of IGESE on Cardiac Marker Enzymes (cTnI and LDH) of DOX-Treated Rats</title><p>Single intraperitoneal injection of DOX resulted in significant (<italic>p</italic> &#x0003c; 0.0001) increases in the serum LDH and cTnI levels when compared to that of untreated negative control (Group I) values (<xref rid="tab8" ref-type="table">Table 8</xref>). However, with oral pretreatments with 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> significantly attenuated (<italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001) increases in the serum cTnI and LDH levels dose dependently (<xref rid="tab8" ref-type="table">Table 8</xref>), and these attenuations were comparable to that induced by oral pretreatment with 20&#x02009;mg/kg/day of Vit. C (<xref rid="tab8" ref-type="table">Table 8</xref>).</p></sec><sec id="sec3.8"><title>3.8. Effect of IGESE on the Serum Lipids (TG, TC, HDL-c, LDL-c) Level of DOX-Treated Rats</title><p>Acute intraperitoneal DOX injection resulted in significant (<italic>p</italic> &#x0003c; 0.05) decreases in the serum TG, significantly (<italic>p</italic> &#x0003c; 0.001) increased serum TC and LDL-c while inducing insignificant (<italic>p</italic> &#x0003e; 0.05) alterations in the serum HDL-c level (<xref rid="tab9" ref-type="table">Table 9</xref>). However, with 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> oral pretreatment, there were significant (<italic>p</italic> &#x0003c; 0.05 and p&#x0003c;0.0001) dose-related increases in the serum TG and HDL-c concentrations, while there were significant (<italic>p</italic> &#x0003e; 0.05 and <italic>p</italic> &#x0003c; 0.001) decreases in the serum TC and LDL-c concentrations when compared to DOX-only treated rats (<xref rid="tab9" ref-type="table">Table 9</xref>). Oral pretreatment with 20&#x02009;mg/kg/day of vitamin C elicited similar effects on the measured serum lipids parameters (<xref rid="tab9" ref-type="table">Table 9</xref>).</p></sec><sec id="sec3.9"><title>3.9. Effect of Oral IGESE Pretreatment on Cardiovascular Risk Indices (AI and CRI) of DOX-Treated Rats</title><p>Acute intraperitoneal injections with DOX resulted in significant (<italic>p</italic> &#x0003c; 0.001) increases in the AI and CRI values when compared to Groups I and II values (<xref rid="tab10" ref-type="table">Table 10</xref>). However, with oral pretreatment with 100-400&#x02009;mg/kg/day of <italic>IGESE</italic>, there were significant (<italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001) dose-related decreases in the AI and CRI values with similar effect induced by oral pretreatments with 20&#x02009;mg/kg/day of Vit. C (<xref rid="tab10" ref-type="table">Table 10</xref>).</p></sec><sec id="sec3.10"><title>3.10. Histopathological Studies of the Effect of IGESE Oral Pretreatment on DOX-Intoxicated Treated Heart</title><p>
<xref ref-type="fig" rid="fig2">Figure 2</xref> is a photomicrograph of a cross-sectional representative of DOX-only treated heart showing myocyte congestion and antemortem coronary microthrombi when compared to untreated normal (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and <italic>IGESE</italic>-only treated heart tissues with normal cardiac architecture (<xref ref-type="fig" rid="fig4">Figure 4</xref>). However, pretreatment with varying doses of <italic>IGESE</italic> resulted in dose-related improvements in the histological distortions induced by DOX especially at 200&#x02009;mg/kg/day (<xref ref-type="fig" rid="fig5">Figure 5</xref>) and 400&#x02009;mg/kg/day of <italic>IGESE</italic> (<xref ref-type="fig" rid="fig6">Figure 6</xref>); although, histological features of vascular congestion were still seen with 100&#x02009;mg/kg/day of <italic>IGESE</italic> oral pretreatment (<xref ref-type="fig" rid="fig7">Figure 7</xref>). On the contrary, there were histological features of persistent coronary microthrombi in rat heart pretreated with 20&#x02009;mg/kg/day of Vit. C, indicating the lingering DOX-induced histological lesions, even with the standard antioxidant drug (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The clinical use of doxorubicin in the management of solid and hematological cancers has been widely limited by its off-target severe cardiotoxicity which manifests biochemically by elevation of serum enzyme markers of cardiotoxicity. The diagnostic serum marker enzymes of cardiotoxicity are AST, ALT, CK-MB, LDH, and cTnI which leak from cardiac tissue damage to the bloodstream due to their tissue specificity and serum catalytic activity [<xref rid="B46" ref-type="bibr">46</xref>]. DOX administration may result in the damage to the myocardial cell membrane or make myocytes more permeable, resulting in the leakage of the diagnostic cardiac enzyme markers cardiac AST, ALT, CK-MB, LDH, and cTnI into the bloodstream and their high circulating levels. In the present study, DOX-mediated cardiotoxicity was fully established as evidenced by the profound elevations in the serum cTnI and LDH levels which is in complete agreement with previous studies [<xref rid="B47" ref-type="bibr">47</xref>&#x02013;<xref rid="B52" ref-type="bibr">52</xref>]. With oral <italic>IGESE</italic> pretreatments, the serum levels of cTnI and LDH were profoundly attenuated toward normal serum level indicating the ameliorative potential of <italic>IGESE</italic> in DOX-mediated cardiotoxicity. These effects were probably mediated through high antioxidant and/or free radical scavenging activities of <italic>IGESE</italic> on the myocardium, thus reducing the damaging effects of DOX to the cardiac muscle fibers, subsequently minimizing the leakage of such enzymes in the serum. Similarly, ROS-mediated mechanism is one of the proposed DOX-mediated cardiotoxicity mechanisms, leading to oxidative stress that causes cardiomyopathy [<xref rid="B53" ref-type="bibr">53</xref>]. Oxidative stress has been reported to increase lipid peroxidation as indicated by an increase in MDA levels and altered enzymatic and nonenzymatic antioxidant systems [<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>]. In this study, MDA level was profoundly increased by DOX treatment, while DOX treatment also suppressed the cardiac tissue activities of SOD, CAT, GPx, GST, and GSH levels in the treated rats in agreement with other studies. These altered biochemical alterations were supported by histological lesions characterized by myocyte congestion and coronary intravascular microthrombi formation. DOX has been previously reported to profoundly reduce vascular blood flow, disintegrate vascular endothelium, and promote GPIIb/IIIa-mediated platelet adhesion and aggregation, all resulting in microthrombi formation [<xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>]. The fact that <italic>IGESE</italic> prevented microthrombi formation in DOX-treated coronary vasculature as evidenced by histopathological results of this study highlighted the possible inherent antithrombotic potential of <italic>IGESE</italic>; although, further studies are still needed in this respect in order to validate this hypothesis. However, <italic>IGESE</italic> profoundly attenuated significant alterations in the cardiac tissue oxidative markers whose activities were significantly suppressed by DOX intoxication. <italic>IGESE</italic> has the tendency to neutralize ROS like superoxide radicals, singlet oxygen, nitric oxide, and peroxynitrite, thereby reducing the damage to lipid membranes [<xref rid="B39" ref-type="bibr">39</xref>]. Similarly, oral <italic>IGESE</italic> pretreatments profoundly improved and reversed the DOX-induced histological lesions especially at 200&#x02009;mg/kg/day and 400&#x02009;mg/kg/day of <italic>IGESE</italic> pretreatments.</p><p>The effects of DOX on serum lipids are also significant. DOX has been reported to cause hyperlipidemia (which include increased serum cholesterol, triglyceride, LDL-c, and FFAs) [<xref rid="B59" ref-type="bibr">59</xref>&#x02013;<xref rid="B64" ref-type="bibr">64</xref>] and increases cardiovascular disease risk [<xref rid="B65" ref-type="bibr">65</xref>]. This hyperlipidemia is thought to be mediated via downregulation of PPAR-<italic>&#x003b3;</italic> and subsequently affect GLUT4 and FAT/CD36 expression resulting in glucose and fatty acid transporters expression and causing hyperglycemia and hyperlipidemia [<xref rid="B65" ref-type="bibr">65</xref>]. <italic>Irvingia gabonensis</italic> seeds have been reported to induce weight loss, antihyperlipidemia, and reduced cardiovascular disease risk factors in both animal [<xref rid="B59" ref-type="bibr">59</xref>&#x02013;<xref rid="B64" ref-type="bibr">64</xref>] and human studies [<xref rid="B66" ref-type="bibr">66</xref>&#x02013;<xref rid="B72" ref-type="bibr">72</xref>] which were reportedly mediated via downregulation of the PPAR-<italic>&#x003b3;</italic> and leptin genes and upregulation of the adiponectin gene mechanisms [<xref rid="B67" ref-type="bibr">67</xref>]. Thus, the results of this study are in tandem with those of earlier studies.</p><p>The GC-MS analysis and phytoscan of <italic>IGESE</italic> are also notably significant. <italic>IGESE</italic> is shown to contain high contents of 4,6-di-O-methyl-alpha-d-galactose, <italic>n</italic>-hexadecanoic acid, undecanoic acid, 9,12,15-octadecatrienoic acid, <italic>&#x003b3;</italic>-sitosterol, phytol, neophytadiene, ethyl 9,12,15-octadecatrienoate, stigmasterol, vitamin E, hexadecanoic acid ethyl ester, Phytyl palmitate, campesterol, and lupeol. Phytosterols such as sitosterol, stigmasterol, campesterol, and phytols have been reported to effectively mitigate lipid peroxidation through antioxidant and free radical scavenging mechanisms and physically stabilize cell membrane [<xref rid="B73" ref-type="bibr">73</xref>] as well as effectively lowered cholesterol especially the LDL-c fraction [<xref rid="B74" ref-type="bibr">74</xref>&#x02013;<xref rid="B78" ref-type="bibr">78</xref>]. Similarly, stigmasterol, <italic>&#x003b3;</italic>-sitosterol, lupeol, lupeol acetate, and <italic>&#x003b1;</italic>-amyrin are known to exhibit other important pharmacological activities such as anticancer, anti-inflammatory, and antibacterial activities [<xref rid="B79" ref-type="bibr">79</xref>]. Lupeol in particular is known to mediate anti-inflammatory, antimicrobial, antiprotozoal, antiproliferative, anti-invasive, antiangiogenic, and cholesterol-lowering activities [<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>]. Phytol is an important diterpene that possesses antimicrobial, antioxidant, and anticancer activities [<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>]. Hexadecanoic acid is known to exhibit strong antimicrobial and anti-inflammatory activity [<xref rid="B83" ref-type="bibr">83</xref>]. Squalene, a triterpene, is a natural antioxidant [<xref rid="B84" ref-type="bibr">84</xref>], possessing various other pharmacological properties including antimicrobial property [<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>]. Neophytadiene is a good analgesic, antipyretic, anti-inflammatory, antimicrobial, and antioxidant compound [<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>]. Thus, the presence of stigmasterol, <italic>&#x003b3;</italic>-sitosterol, lupeol, phytols, and neophytadiene in high amounts in <italic>IGESE</italic> could be responsible for the cholesterol-lowering, antioxidant, and antilipiperoxidation activities of <italic>IGESE</italic> in DOX-mediated cardiotoxic rats. Similarly, flavonoids, steroids, cardiac glycosides, tannin, and saponin have been reported to elicit antithrombotic activities [<xref rid="B89" ref-type="bibr">89</xref>&#x02013;<xref rid="B91" ref-type="bibr">91</xref>], and more specifically, plant-derived sitosterol has been reported to have anticoagulant and thrombus-preventing activities in mice [<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>]. Thus, the presence of these phytochemicals especially steroids and tannin in high amounts in <italic>IGESE</italic> could be responsible for the observed antithrombotic action of <italic>IGESE</italic> in DOX-intoxicated rats.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>Overall, results of this study showed that <italic>IGESE</italic> effectively attenuated DOX-mediated cardiotoxicity and its cardioprotective activities were mediated via antioxidant, free radical scavenging, antilipoperoxidation, and antithrombotic mechanisms.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors deeply appreciate the technical assistance provided by the Laboratory Manager, Dr. Sarah John-Olabode, and other staff of the Laboratory Services, AFRIGLOBAL MEDICARE, Mobolaji Bank Anthony Branch Office, Ikeja, Lagos, Nigeria, in assaying for the serum cardiac biomarkers and lipid profile. Similarly, the technical support of staff of LASUCOM Animal House, for the care of the Experimental Animals used for this study and Mr. Sunday Adenekan of BIOLIFE CONSULTS in the area of oxidative stress markers analysis are much appreciated. This research was funded by the Tertiary Education Trust Fund (TETFUND) Nigeria, through its National Research Fund (TETFUND/NRF/UIL/ILORIN/STI/VOL.1/B2.20.12) as a collaborative research award to Professors Olufunke Olorundare, Phillip Kolo, and Hasan Mukhtar.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>AI:</term><def><p>Atherogenic index</p></def></def-item><def-item><term>ALT:</term><def><p>Alanine transaminase</p></def></def-item><def-item><term>AST:</term><def><p>Aspartate transaminase</p></def></def-item><def-item><term>CAT:</term><def><p>Catalase</p></def></def-item><def-item><term>CK-MB:</term><def><p>Creatine kinase-MB</p></def></def-item><def-item><term>CRI:</term><def><p>Coronary artery index</p></def></def-item><def-item><term>DMSO:</term><def><p>Dimethyl sulfoxide</p></def></def-item><def-item><term>DNA:</term><def><p>Deoxyribonucleic acid</p></def></def-item><def-item><term>DOX:</term><def><p>Doxorubicin</p></def></def-item><def-item><term>DPPH:</term><def><p>1,1-diphenyl-2-picrylhydrazyl</p></def></def-item><def-item><term>FAT/CD36:</term><def><p>Fatty acid translocase</p></def></def-item><def-item><term>FFAs:</term><def><p>Free fatty acids</p></def></def-item><def-item><term>FRAP:</term><def><p>Ferric reducing activity power</p></def></def-item><def-item><term>GC-MS:</term><def><p>Gas chromatography mass spectrometer</p></def></def-item><def-item><term>GLUT4:</term><def><p>Glucose transporter member 4</p></def></def-item><def-item><term>GPIIb/IIIa:</term><def><p>Glycoprotein IIb/IIIa</p></def></def-item><def-item><term>GPx:</term><def><p>Glutathione peroxidase</p></def></def-item><def-item><term>GSH:</term><def><p>Reduced glutathione</p></def></def-item><def-item><term>GST:</term><def><p>Glutathione S-transferase</p></def></def-item><def-item><term>HDL-c:</term><def><p>High density lipoprotein cholesterol</p></def></def-item><def-item><term><italic>i.p.</italic>:</term><def><p>Intraperitoneal</p></def></def-item><def-item><term><italic>IGESE</italic>:</term><def><p>
<italic>Irginvia gabonensis</italic> ethanol seed extract</p></def></def-item><def-item><term>KCl:</term><def><p>Potassium chloride</p></def></def-item><def-item><term>LDH:</term><def><p>Lactate dehydrogenase</p></def></def-item><def-item><term>LDL-c:</term><def><p>Low density lipoprotein cholesterol</p></def></def-item><def-item><term>MDA:</term><def><p>Malondialdehyde</p></def></def-item><def-item><term>NO:</term><def><p>Nitric oxide</p></def></def-item><def-item><term><italic>p.o.</italic>:</term><def><p>
<italic>Per os</italic>
</p></def></def-item><def-item><term>PPAR<italic>&#x003b3;</italic>:</term><def><p>Peroxisome proliferator-activator receptor gamma</p></def></def-item><def-item><term>ROS:</term><def><p>Reactive oxygen species</p></def></def-item><def-item><term>rpm:</term><def><p>Revolution per minute</p></def></def-item><def-item><term>S.E.M.:</term><def><p>Standard error of the mean</p></def></def-item><def-item><term>SOD:</term><def><p>Superoxidase dismutase</p></def></def-item><def-item><term>TC:</term><def><p>Total cholesterol</p></def></def-item><def-item><term>TG:</term><def><p>Triglyceride</p></def></def-item><def-item><term>UERC:</term><def><p>UNILORIN ethics and research committee</p></def></def-item><def-item><term>UNILORIN:</term><def><p>University of Ilorin</p></def></def-item><def-item><term>Vit. C:</term><def><p>Vitamin C.</p></def></def-item></def-list></glossary><sec sec-type="data-availability"><title>Data Availability</title><p>Answer: Yes. Comment</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors have none to declare.</p></sec><sec><title>Authors' Contributions</title><p>Olufunke Olorundare designed the experimental protocol for this study and was involved in the manuscript writing; Adejuwon Adeneye supervised the research, analyzed data, and wrote the manuscript; Akinyele Akinsola and Olalekan Agede are postgraduate students in Olufunke Olorundare's laboratory that performed the laboratory research under supervision; Phillip Kolo was part of the protocol design and read through the manuscript; Ikechukwu Okoye prepared the cardiac tissue slides; Sunday Soyemi and Alban Mgbehoma independently read and interpreted the cardiac tissue slides; Ralph Albrecht and Hasan Mukhtar are our collaborators in the U.S.A. who read through the manuscript.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>P. A.</given-names></name></person-group><article-title>Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention</article-title><source><italic toggle="yes">Heart</italic></source><year>2018</year><volume>104</volume><issue>12</issue><fpage>971</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2017-312103</pub-id><pub-id pub-id-type="other">2-s2.0-85050384775</pub-id><?supplied-pmid 29217634?><pub-id pub-id-type="pmid">29217634</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pommier</surname><given-names>Y.</given-names></name><name><surname>Leo</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Marchand</surname><given-names>C.</given-names></name></person-group><article-title>DNA topoisomerases and their poisoning by anticancer and antibacterial drugs</article-title><source><italic toggle="yes">Chemistry &#x00026; Biology</italic></source><year>2010</year><volume>17</volume><issue>5</issue><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2010.04.012</pub-id><pub-id pub-id-type="other">2-s2.0-77954187741</pub-id><?supplied-pmid 20534341?><pub-id pub-id-type="pmid">20534341</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacar</surname><given-names>O.</given-names></name><name><surname>Sriamornsak</surname><given-names>P.</given-names></name><name><surname>Dass</surname><given-names>C. R.</given-names></name></person-group><article-title>Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems</article-title><source><italic toggle="yes">The Journal of Pharmacy and Pharmacology</italic></source><year>2013</year><volume>65</volume><issue>2</issue><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2012.01567.x</pub-id><pub-id pub-id-type="other">2-s2.0-84871711842</pub-id><?supplied-pmid 23278683?><pub-id pub-id-type="pmid">23278683</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>B.</given-names></name><name><surname>Qiao</surname><given-names>X.</given-names></name><name><surname>Janssen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2013</year><volume>4</volume><issue>1, article 1908</issue><pub-id pub-id-type="doi">10.1038/ncomms2921</pub-id><pub-id pub-id-type="other">2-s2.0-84878732407</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kropp</surname><given-names>J.</given-names></name><name><surname>Roti Roti</surname><given-names>E. C.</given-names></name><name><surname>Ringelstetter</surname><given-names>A.</given-names></name><name><surname>Khatib</surname><given-names>H.</given-names></name><name><surname>Abbott</surname><given-names>D. H.</given-names></name><name><surname>Salih</surname><given-names>S. M.</given-names></name></person-group><article-title>Dexrazoxane diminishes doxorubicin-induced acute ovarian damage and preserves ovarian function and fecundity in mice</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2015</year><volume>10</volume><issue>11, article e0142588</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0142588</pub-id><pub-id pub-id-type="other">2-s2.0-84952705632</pub-id><?supplied-pmid 26544188?><pub-id pub-id-type="pmid">26544188</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>L. A.</given-names></name><name><surname>Cornelius</surname><given-names>V. R.</given-names></name><name><surname>Plummer</surname><given-names>C. J.</given-names></name><etal/></person-group><article-title>Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials</article-title><source><italic toggle="yes">BMC Cancer</italic></source><year>2010</year><volume>10</volume><issue>1</issue><fpage>p. 337</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-10-337</pub-id><pub-id pub-id-type="other">2-s2.0-77953931502</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spallarossa</surname><given-names>P.</given-names></name><name><surname>Maurea</surname><given-names>N.</given-names></name><name><surname>Cadeddu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology</article-title><source><italic toggle="yes">Journal of Cardiovascular Medicine</italic></source><year>2016</year><volume>17</volume><issue>Supplement 1</issue><fpage>e84</fpage><lpage>e92</lpage><pub-id pub-id-type="doi">10.2459/JCM.0000000000000381</pub-id><pub-id pub-id-type="other">2-s2.0-84969945010</pub-id><pub-id pub-id-type="pmid">27755246</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menna</surname><given-names>P.</given-names></name><name><surname>Salvatorelli</surname><given-names>E.</given-names></name></person-group><article-title>Primary prevention strategies for anthracycline cardiotoxicity: a brief overview</article-title><source><italic toggle="yes">Chemotherapy</italic></source><year>2017</year><volume>62</volume><issue>3</issue><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1159/000455823</pub-id><pub-id pub-id-type="other">2-s2.0-85010908044</pub-id><pub-id pub-id-type="pmid">28122377</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engert</surname><given-names>A.</given-names></name><name><surname>Franklin</surname><given-names>J.</given-names></name><name><surname>Eich</surname><given-names>H. T.</given-names></name><etal/></person-group><article-title>Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial</article-title><source><italic toggle="yes">Journal of Clinical Oncology</italic></source><year>2007</year><volume>25</volume><issue>23</issue><fpage>3495</fpage><lpage>3502</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.07.0482</pub-id><pub-id pub-id-type="other">2-s2.0-34548186696</pub-id><?supplied-pmid 17606976?><pub-id pub-id-type="pmid">17606976</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brayfield</surname><given-names>A.</given-names></name></person-group><source><italic toggle="yes">Doxorubicin in: Martindale: The Complete Drug Reference</italic></source><year>2013</year><publisher-loc>London</publisher-loc><publisher-name>Pharmaceutical Press</publisher-name></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Ding</surname><given-names>X.-F.</given-names></name><name><surname>Shen</surname><given-names>J.-Y.</given-names></name><name><surname>Zhang</surname><given-names>X. P.</given-names></name><name><surname>Ding</surname><given-names>X. W.</given-names></name><name><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice</article-title><source><italic toggle="yes">Journal of Zhejiang University. Science. B</italic></source><year>2017</year><volume>18</volume><issue>1</issue><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1631/jzus.B1600303</pub-id><pub-id pub-id-type="other">2-s2.0-85009945311</pub-id><?supplied-pmid 28070993?><pub-id pub-id-type="pmid">28070993</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magni</surname><given-names>M.</given-names></name><name><surname>Biancon</surname><given-names>G.</given-names></name><name><surname>Rizzitano</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma</article-title><source><italic toggle="yes">British Journal of Cancer</italic></source><year>2019</year><volume>121</volume><issue>7</issue><fpage>567</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/s41416-019-0557-8</pub-id><pub-id pub-id-type="other">2-s2.0-85072029033</pub-id><?supplied-pmid 31474759?><pub-id pub-id-type="pmid">31474759</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczmarek</surname><given-names>A.</given-names></name><name><surname>Brinkman</surname><given-names>B. M.</given-names></name><name><surname>Heyndrickx</surname><given-names>L.</given-names></name><name><surname>Vandenabeele</surname><given-names>P.</given-names></name><name><surname>Krysko</surname><given-names>D. V.</given-names></name></person-group><article-title>Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways</article-title><source><italic toggle="yes">The Journal of Pathology</italic></source><year>2012</year><volume>226</volume><issue>4</issue><fpage>598</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1002/path.3009</pub-id><pub-id pub-id-type="other">2-s2.0-84856691714</pub-id><?supplied-pmid 21960132?><pub-id pub-id-type="pmid">21960132</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname><given-names>S. M.</given-names></name><name><surname>Whaley</surname><given-names>F. S.</given-names></name><name><surname>Ewer</surname><given-names>M. S.</given-names></name></person-group><article-title>Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials</article-title><source><italic toggle="yes">Cancer</italic></source><year>2003</year><volume>97</volume><issue>11</issue><fpage>2869</fpage><lpage>2879</lpage><pub-id pub-id-type="doi">10.1002/cncr.11407</pub-id><pub-id pub-id-type="other">2-s2.0-0038521374</pub-id><?supplied-pmid 12767102?><pub-id pub-id-type="pmid">12767102</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feijen</surname><given-names>E. A. M.</given-names></name><name><surname>Leisenring</surname><given-names>W. M.</given-names></name><name><surname>Stratton</surname><given-names>K. L.</given-names></name><etal/></person-group><article-title>Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity</article-title><source><italic toggle="yes">JAMA Oncology</italic></source><year>2019</year><volume>5</volume><issue>6</issue><fpage>864</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.6634</pub-id><pub-id pub-id-type="other">2-s2.0-85061009830</pub-id><?supplied-pmid 30703192?><pub-id pub-id-type="pmid">30703192</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodoulou</surname><given-names>M.</given-names></name><name><surname>Hudis</surname><given-names>C.</given-names></name></person-group><article-title>Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?</article-title><source><italic toggle="yes">Cancer</italic></source><year>2004</year><volume>100</volume><issue>10</issue><fpage>2052</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1002/cncr.20207</pub-id><pub-id pub-id-type="other">2-s2.0-2342488025</pub-id><?supplied-pmid 15139046?><pub-id pub-id-type="pmid">15139046</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Honbo</surname><given-names>N.</given-names></name><name><surname>Karliner</surname><given-names>J. S.</given-names></name></person-group><article-title>Doxorubicin cardiomyopathy</article-title><source><italic toggle="yes">Cardiology</italic></source><year>2010</year><volume>115</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1159/000265166</pub-id><pub-id pub-id-type="other">2-s2.0-72049093531</pub-id><?supplied-pmid 20016174?><pub-id pub-id-type="pmid">20016174</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGowan</surname><given-names>J. V.</given-names></name><name><surname>Chung</surname><given-names>R.</given-names></name><name><surname>Maulik</surname><given-names>A.</given-names></name><name><surname>Piotrowska</surname><given-names>I.</given-names></name><name><surname>Walker</surname><given-names>J. M.</given-names></name><name><surname>Yellon</surname><given-names>D. M.</given-names></name></person-group><article-title>Anthracycline chemotherapy and cardiotoxicity</article-title><source><italic toggle="yes">Cardiovascular Drugs and Therapy</italic></source><year>2017</year><volume>31</volume><issue>1</issue><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s10557-016-6711-0</pub-id><pub-id pub-id-type="other">2-s2.0-85011903694</pub-id><?supplied-pmid 28185035?><pub-id pub-id-type="pmid">28185035</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00160;t&#x0011b;rba</surname><given-names>M.</given-names></name><name><surname>Popelov&#x000e1;</surname><given-names>O.</given-names></name><name><surname>V&#x000e1;vrov&#x000e1;</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection</article-title><source><italic toggle="yes">Antioxidants &#x00026; Redox Signaling</italic></source><year>2013</year><volume>18</volume><issue>8</issue><fpage>899</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1089/ars.2012.4795</pub-id><pub-id pub-id-type="other">2-s2.0-84873836880</pub-id><?supplied-pmid 22794198?><pub-id pub-id-type="pmid">22794198</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalay</surname><given-names>N.</given-names></name><name><surname>Basar</surname><given-names>E.</given-names></name><name><surname>Ozdogru</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Protective effects of carvedilol against anthracycline-induced cardiomyopathy</article-title><source><italic toggle="yes">Journal of the American College of Cardiology</italic></source><year>2006</year><volume>48</volume><issue>11</issue><fpage>2258</fpage><lpage>2262</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2006.07.052</pub-id><pub-id pub-id-type="other">2-s2.0-33845206791</pub-id><?supplied-pmid 17161256?><pub-id pub-id-type="pmid">17161256</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>F.</given-names></name><name><surname>Luis</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment (Review)</article-title><source><italic toggle="yes">Molecular and Clinical Oncology</italic></source><year>2019</year><volume>11</volume><issue>1</issue><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.3892/mco.2019.1854</pub-id><pub-id pub-id-type="other">2-s2.0-85070726653</pub-id><?supplied-pmid 31289672?><pub-id pub-id-type="pmid">31289672</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiserov&#x000e1;</surname><given-names>H.</given-names></name><name><surname>&#x00160;im&#x0016f;nek</surname><given-names>T.</given-names></name><name><surname>van der Vijgh</surname><given-names>W. J. F.</given-names></name><name><surname>Bast</surname><given-names>A.</given-names></name><name><surname>Kvasni&#x0010d;kov&#x000e1;</surname><given-names>E.</given-names></name></person-group><article-title>Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase</article-title><source><italic toggle="yes">Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseBiochimica et Biophysica Acta</italic></source><year>2007</year><volume>1772</volume><issue>9</issue><fpage>1065</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2007.05.002</pub-id><pub-id pub-id-type="other">2-s2.0-34548179685</pub-id><?supplied-pmid 17572073?><pub-id pub-id-type="pmid">17572073</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minotti</surname><given-names>G.</given-names></name><name><surname>Menna</surname><given-names>P.</given-names></name><name><surname>Salvatorelli</surname><given-names>E.</given-names></name><name><surname>Cairo</surname><given-names>G.</given-names></name><name><surname>Gianni</surname><given-names>L.</given-names></name></person-group><article-title>Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity</article-title><source><italic toggle="yes">Pharmacological Reviews</italic></source><year>2004</year><volume>56</volume><issue>2</issue><fpage>185</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1124/pr.56.2.6</pub-id><pub-id pub-id-type="other">2-s2.0-2642566088</pub-id><pub-id pub-id-type="pmid">15169927</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Che</surname><given-names>F. F.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>C. G.</given-names></name></person-group><article-title>Study on the effect and mechanism of dextromethionine on cardiotoxicity induced by doxorubicin</article-title><source><italic toggle="yes">Journal of Sichuan University</italic></source><year>2010</year><volume>41</volume><fpage>24</fpage><lpage>28</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name></person-group><article-title>Observation of the effects of dextromethine on cardiotoxicity induced by epirubicin</article-title><source><italic toggle="yes">Chinese Journal of Cancer Prevention and Treatment</italic></source><year>2010</year><volume>17</volume><fpage>296</fpage><lpage>298</lpage></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>G.</given-names></name><name><surname>Bigioni</surname><given-names>M.</given-names></name><name><surname>Evangelista</surname><given-names>S.</given-names></name><name><surname>Goso</surname><given-names>C.</given-names></name><name><surname>Manzini</surname><given-names>S.</given-names></name><name><surname>Maggi</surname><given-names>C. A.</given-names></name></person-group><article-title>Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat</article-title><source><italic toggle="yes">European Journal of Pharmacology</italic></source><year>2001</year><volume>414</volume><issue>1</issue><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(01)00782-8</pub-id><pub-id pub-id-type="other">2-s2.0-0035936864</pub-id><pub-id pub-id-type="pmid">11230997</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>G.</given-names></name><name><surname>Bigioni</surname><given-names>M.</given-names></name><name><surname>Lopez</surname><given-names>G.</given-names></name><name><surname>Evangelista</surname><given-names>S.</given-names></name><name><surname>Manzini</surname><given-names>S.</given-names></name><name><surname>Maggi</surname><given-names>C. A.</given-names></name></person-group><article-title>ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat</article-title><source><italic toggle="yes">Vascular Pharmacology</italic></source><year>2009</year><volume>50</volume><issue>5-6</issue><fpage>166</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2009.01.001</pub-id><pub-id pub-id-type="other">2-s2.0-61449181080</pub-id><?supplied-pmid 19344651?><pub-id pub-id-type="pmid">19344651</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavrova</surname><given-names>A.</given-names></name><name><surname>Jansova</surname><given-names>H.</given-names></name><name><surname>Mackova</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>10, article e76676</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0076676</pub-id><pub-id pub-id-type="other">2-s2.0-84885024579</pub-id><?supplied-pmid 24116135?><pub-id pub-id-type="pmid">24116135</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>T.</given-names></name><name><surname>Jendrny</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms</article-title><source><italic toggle="yes">BMC Cancer</italic></source><year>2014</year><volume>14</volume><issue>1</issue><fpage>p. 842</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-14-842</pub-id><pub-id pub-id-type="other">2-s2.0-84965095096</pub-id><pub-id pub-id-type="pmid">25406834</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burkill</surname><given-names>H. M.</given-names></name></person-group><source><italic toggle="yes">The Useful Plants of West Tropical Africa</italic></source><year>1985</year><volume>2</volume><publisher-loc>Kew, London</publisher-loc><publisher-name>Royal Botanic Gardens</publisher-name></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Karalliedde</surname><given-names>L.</given-names></name><name><surname>Gawarammana</surname><given-names>I.</given-names></name></person-group><source><italic toggle="yes">Traditional Herbal Medicines - a Guide to the Safer Use of Herbal Medicines</italic></source><year>2008</year><publisher-loc>London</publisher-loc><publisher-name>Hammersmith Press</publisher-name></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unaeze</surname><given-names>B. C.</given-names></name><name><surname>Ilo</surname><given-names>C. E.</given-names></name><name><surname>Egwuatu</surname><given-names>C.</given-names></name><name><surname>Orabueze</surname><given-names>I.</given-names></name><name><surname>Obi</surname><given-names>E.</given-names></name></person-group><article-title>Anti-diarrhoeal effects of three Nigerian medicinal plant extracts on <italic>E.coli</italic>-induced diarrhea</article-title><source><italic toggle="yes">International Journal of Biological and Chemical Sciences</italic></source><year>2017</year><volume>11</volume><issue>1</issue><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.4314/ijbcs.v11i1.33</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mahunu</surname><given-names>G. K.</given-names></name><name><surname>Quansa</surname><given-names>L.</given-names></name><name><surname>Tahir</surname><given-names>H. E.</given-names></name><name><surname>Mariod</surname><given-names>A. A.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mariod</surname><given-names>A.</given-names></name></person-group><article-title>Irvingia gabonensis: phytochemical constituents, bioactive compounds, traditional and medicinal uses</article-title><source><italic toggle="yes">Wild Fruits: Composition, Nutritional Value and Products</italic></source><year>2019</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Springer Cham</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-030-31885-7_21</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Okogun</surname><given-names>J. I.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Iwu</surname><given-names>M. M.</given-names></name><name><surname>Wootton</surname><given-names>J. C.</given-names></name></person-group><article-title>Drug discovery through ethnobotany in Nigeria: some results</article-title><source><italic toggle="yes">Advances in Phytomedicine - Ethnomedicine and Drug Discovery</italic></source><year>2002</year><volume>1</volume><publisher-loc>London</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/S1572-557X(02)80021-6</pub-id><pub-id pub-id-type="other">2-s2.0-77957082542</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name></person-group><article-title>Ultra high-performance liquid chromatography with high-resolution mass spectrometry analysis of African mango (<italic>Irvingia gabonensis</italic>) seeds, extract, and related dietary supplements</article-title><source><italic toggle="yes">Journal of Agricultural and Food Chemistry</italic></source><year>2012</year><volume>60</volume><issue>35</issue><fpage>8703</fpage><lpage>8709</lpage><pub-id pub-id-type="doi">10.1021/jf302703u</pub-id><pub-id pub-id-type="other">2-s2.0-84865853680</pub-id><?supplied-pmid 22880691?><pub-id pub-id-type="pmid">22880691</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awah</surname><given-names>F. M.</given-names></name><name><surname>Uzoegwu</surname><given-names>P. N.</given-names></name><name><surname>Ifeonu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Free radical scavenging activity, phenolic contents and cytotoxicity of selected Nigerian medicinal plants</article-title><source><italic toggle="yes">Food Chemistry</italic></source><year>2012</year><volume>131</volume><issue>4</issue><fpage>1279</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2011.09.118</pub-id><pub-id pub-id-type="other">2-s2.0-81855161815</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>O. A.</given-names></name><name><surname>Ijeoma</surname><given-names>U. F.</given-names></name></person-group><article-title>Effects of aqueous extracts of <italic>Irvingia gabonensis</italic> seeds on the hormonal parameters of male Guinea pigs</article-title><source><italic toggle="yes">Asian Pacific Journal of Tropical Medicine</italic></source><year>2010</year><volume>3</volume><issue>3</issue><fpage>200</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/s1995-7645(10)60009-0</pub-id><pub-id pub-id-type="other">2-s2.0-77950633608</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Don Lawson</surname><given-names>D. C.</given-names></name></person-group><article-title>Proximate analysis and phytochemical screening of <italic>Irvingia gabonensis</italic> (Ogbono cotyledon)</article-title><source><italic toggle="yes">Biomedical Journal of Scientific &#x00026; Technical Research</italic></source><year>2018</year><volume>5</volume><issue>4</issue><fpage>4643</fpage><lpage>4646</lpage><pub-id pub-id-type="doi">10.26717/bjstr.2018.05.001227</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekpe</surname><given-names>O. O.</given-names></name><name><surname>Nwaehujor</surname><given-names>C. O.</given-names></name><name><surname>Ejiofor</surname><given-names>C. E.</given-names></name><name><surname>Arikpo Peace</surname><given-names>W.</given-names></name><name><surname>Woruji Eliezer</surname><given-names>E.</given-names></name><name><surname>Amor Emmanuel</surname><given-names>T.</given-names></name></person-group><article-title>
<italic>Irvingia gabonensis</italic> seeds extract fractionation, its antioxidant analyses and effects on red blood cell membrane stability</article-title><source><italic toggle="yes">PhOL</italic></source><year>2019</year><volume>1</volume><fpage>337</fpage><lpage>353</lpage></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Trease</surname><given-names>G. E.</given-names></name><name><surname>Evans</surname><given-names>W. C.</given-names></name></person-group><source><italic toggle="yes">A Textbook of Pharmacognosy</italic></source><year>1989</year><publisher-loc>London, UK</publisher-loc><publisher-name>Bailliere Tindall Ltd</publisher-name></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sofowora</surname><given-names>A.</given-names></name></person-group><source><italic toggle="yes">Medicinal Plants and Traditional Medicine in Africa</italic></source><year>1993</year><publisher-loc>Ibadan, Nigeria</publisher-loc><publisher-name>Spectrum Books Ltd</publisher-name></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olorundare</surname><given-names>O. E.</given-names></name><name><surname>Adeneye</surname><given-names>A. A.</given-names></name><name><surname>Akinsola</surname><given-names>A. O.</given-names></name><name><surname>Sanni</surname><given-names>D. A.</given-names></name><name><surname>Koketsu</surname><given-names>M.</given-names></name><name><surname>Mukhtar</surname><given-names>H.</given-names></name></person-group><article-title>
<italic>Clerodendrum</italic> volubile ethanol leaf extract: a potential antidote to doxorubicin-induced cardiotoxicity in rats</article-title><source><italic toggle="yes">Journal of Toxicology</italic></source><year>2020</year><volume>2020</volume><fpage>17</fpage><pub-id pub-id-type="publisher-id">8859716</pub-id><pub-id pub-id-type="doi">10.1155/2020/8859716</pub-id><?supplied-pmid 32714390?><pub-id pub-id-type="pmid">32714390</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="book"><collab>National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals</collab><source><italic toggle="yes">Guide for the Care and Use of Laboratory Animals</italic></source><year>2011</year><publisher-loc>Washington, DC, USA</publisher-loc><publisher-name>The National Academies Press</publisher-name></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>R. D.</given-names></name><name><surname>Wilson</surname><given-names>P. W.</given-names></name><name><surname>Kannel</surname><given-names>W. B.</given-names></name><name><surname>Castelli</surname><given-names>W. P.</given-names></name></person-group><article-title>High density lipoprotein-cholesterol, total cholesterol screening and myocardial infarction: the Framingham study</article-title><source><italic toggle="yes">Arteriosclerosis</italic></source><year>1988</year><volume>8</volume><issue>3</issue><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.8.3.207</pub-id><pub-id pub-id-type="pmid">3370018</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alladi</surname><given-names>S.</given-names></name><name><surname>Shanmugasundaram</surname><given-names>K. R.</given-names></name></person-group><article-title>Induction of hypercholesterolemia by supplementing soy protein with acetate generating amino acids</article-title><source><italic toggle="yes">Nutrition Reports International</italic></source><year>1989</year><volume>40</volume><fpage>893</fpage><lpage>899</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>H. C. M.</given-names></name><name><surname>bin Sattar</surname><given-names>M. M.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Bian</surname><given-names>J. S.</given-names></name></person-group><article-title>Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury</article-title><source><italic toggle="yes">European Journal of Pharmacology</italic></source><year>2011</year><volume>652</volume><issue>1-3</issue><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2010.10.082</pub-id><pub-id pub-id-type="other">2-s2.0-78650914850</pub-id><?supplied-pmid 21114975?><pub-id pub-id-type="pmid">21114975</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polena</surname><given-names>S.</given-names></name><name><surname>Shikara</surname><given-names>M.</given-names></name><name><surname>Naik</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Troponin I as a marker of doxorubicin induced cardiotoxicity</article-title><source><italic toggle="yes">Proceedings of the Western Pharmacology Society</italic></source><year>2005</year><volume>48</volume><fpage>142</fpage><lpage>144</lpage><?supplied-pmid 16416682?><pub-id pub-id-type="pmid">16416682</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahzadi</surname><given-names>A.</given-names></name><name><surname>Sonmez</surname><given-names>I.</given-names></name><name><surname>Allahverdiyev</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Cardiac troponin-I (cTnI) a biomarker of cardiac injuries induced by doxorubicin alone and in combination with ciprofloxacin, following acute and chronic dose protocol in Sprague Dawley rats</article-title><source><italic toggle="yes">International Journal of Pharmacology</italic></source><year>2014</year><volume>10</volume><issue>5</issue><fpage>258</fpage><lpage>266</lpage></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim&#x000f5;es</surname><given-names>R.</given-names></name><name><surname>Silva</surname><given-names>L. M.</given-names></name><name><surname>Cruz</surname><given-names>A. L. V. M.</given-names></name><name><surname>Fraga</surname><given-names>V. G.</given-names></name><name><surname>de Paula Sabino</surname><given-names>A.</given-names></name><name><surname>Gomes</surname><given-names>K. B.</given-names></name></person-group><article-title>Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: a narrative review</article-title><source><italic toggle="yes">Biomedicine &#x00026; Pharmacotherapy</italic></source><year>2018</year><volume>107</volume><fpage>989</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.08.035</pub-id><pub-id pub-id-type="other">2-s2.0-85051919991</pub-id><pub-id pub-id-type="pmid">30257411</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zilinyi</surname><given-names>R.</given-names></name><name><surname>Czompa</surname><given-names>A.</given-names></name><name><surname>Czegledi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: the role of autophagy</article-title><source><italic toggle="yes">Molecules</italic></source><year>2018</year><volume>23</volume><issue>5, article 1184</issue><pub-id pub-id-type="doi">10.3390/molecules23051184</pub-id><pub-id pub-id-type="other">2-s2.0-85047178739</pub-id><?supplied-pmid 29762537?><pub-id pub-id-type="pmid">29762537</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>M. F.</given-names></name><name><surname>Khan</surname><given-names>G.</given-names></name><name><surname>Safhi</surname><given-names>M. M.</given-names></name><etal/></person-group><article-title>Thymoquinone ameliorates doxorubicin-induced cardiotoxicity in Swiss albino mice by modulating oxidative damage and cellular inflammation</article-title><source><italic toggle="yes">Cardiology Research and Practice</italic></source><year>2018</year><volume>2018</volume><fpage>6</fpage><pub-id pub-id-type="publisher-id">1483041</pub-id><pub-id pub-id-type="doi">10.1155/2018/1483041</pub-id><pub-id pub-id-type="other">2-s2.0-85045648273</pub-id><?supplied-pmid 29805796?><pub-id pub-id-type="pmid">29805796</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamcova</surname><given-names>M.</given-names></name><name><surname>Skarkova</surname><given-names>V.</given-names></name><name><surname>Seifertova</surname><given-names>J.</given-names></name><name><surname>Rudolf</surname><given-names>E.</given-names></name></person-group><article-title>Cardiac troponins are among targets of doxorubicin-induced cardiotoxicity in hiPCS-CMs</article-title><source><italic toggle="yes">International Journal of Molecular Sciences</italic></source><year>2019</year><volume>20</volume><issue>11, article 2638</issue><pub-id pub-id-type="doi">10.3390/ijms20112638</pub-id><pub-id pub-id-type="other">2-s2.0-85067277508</pub-id><?supplied-pmid 31146354?><pub-id pub-id-type="pmid">31146354</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>E. K. C.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Sanderson</surname><given-names>J. E.</given-names></name><name><surname>Chen</surname><given-names>K. B.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>C. M.</given-names></name></person-group><article-title>A novel anti-fibrotic agent, baicalein for the treatment of myocardial fibrosis in spontaneously hypertensive rats</article-title><source><italic toggle="yes">European Journal of Pharmacology</italic></source><year>2011</year><volume>658</volume><issue>2-3</issue><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2011.02.033</pub-id><pub-id pub-id-type="other">2-s2.0-79953800506</pub-id><?supplied-pmid 21371455?><pub-id pub-id-type="pmid">21371455</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>B. A.</given-names></name><name><surname>Crapo</surname><given-names>J. D.</given-names></name></person-group><article-title>Biology of disease free radicals and tissue injury</article-title><source><italic toggle="yes">Laboratory Investigation</italic></source><year>1982</year><volume>47</volume><issue>5</issue><fpage>412</fpage><lpage>426</lpage><?supplied-pmid 6290784?><pub-id pub-id-type="pmid">6290784</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gawe&#x00142;</surname><given-names>S.</given-names></name><name><surname>Wardas</surname><given-names>M.</given-names></name><name><surname>Niedwork</surname><given-names>E.</given-names></name><name><surname>Wardas</surname><given-names>P.</given-names></name></person-group><article-title>Malondialdehyde (MDA) as a lipid peroxidation marker</article-title><source><italic toggle="yes">Wiadomosci Lekarskie</italic></source><year>2004</year><volume>57</volume><issue>9-10</issue><fpage>453</fpage><lpage>455</lpage><?supplied-pmid 15765761?><pub-id pub-id-type="pmid">15765761</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Lim</surname><given-names>K. M.</given-names></name><name><surname>Noh</surname><given-names>J. Y.</given-names></name><etal/></person-group><article-title>Doxorubicin-induced platelet procoagulant activities: an important clue for chemotherapy-associated thrombosis</article-title><source><italic toggle="yes">Toxicological Sciences</italic></source><year>2011</year><volume>124</volume><issue>1</issue><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfr222</pub-id><pub-id pub-id-type="other">2-s2.0-84155175860</pub-id><pub-id pub-id-type="pmid">21865289</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Aharon</surname><given-names>I.</given-names></name><name><surname>Bar Joseph</surname><given-names>H.</given-names></name><name><surname>Tzabari</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Doxorubicin-induced vascular toxicity &#x02013; targeting potential pathways may reduce procoagulant activity</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>9, article e75157</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0075157</pub-id><pub-id pub-id-type="other">2-s2.0-84884471239</pub-id><?supplied-pmid 24073244?><pub-id pub-id-type="pmid">24073244</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>R.</given-names></name><name><surname>Liao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Doxorubicin contributes to thrombus formation and vascular injury by interfering with platelet function</article-title><source><italic toggle="yes">American Journal of Physiology-Heart and Circulatory Physiology</italic></source><year>2020</year><volume>319</volume><issue>1</issue><fpage>H133</fpage><lpage>H143</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00456.2019</pub-id><?supplied-pmid 32469636?><pub-id pub-id-type="pmid">32469636</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samelis</surname><given-names>G. F.</given-names></name><name><surname>Stathopoulos</surname><given-names>G. P.</given-names></name><name><surname>Kotsarelis</surname><given-names>D.</given-names></name><name><surname>Dontas</surname><given-names>I.</given-names></name><name><surname>Frangia</surname><given-names>C.</given-names></name><name><surname>Karayannacos</surname><given-names>P. E.</given-names></name></person-group><article-title>Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187)</article-title><source><italic toggle="yes">Anticancer Research</italic></source><year>1998</year><volume>18</volume><issue>5A</issue><fpage>3305</fpage><lpage>3309</lpage><?supplied-pmid 9858900?><pub-id pub-id-type="pmid">9858900</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>Y. M.</given-names></name><name><surname>Kim</surname><given-names>H. S.</given-names></name><name><surname>Yoon</surname><given-names>H.-R.</given-names></name></person-group><article-title>Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine</article-title><source><italic toggle="yes">Pediatric Research</italic></source><year>2002</year><volume>51</volume><issue>2</issue><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1203/00006450-200202000-00020</pub-id><pub-id pub-id-type="other">2-s2.0-0036152295</pub-id><?supplied-pmid 11809922?><pub-id pub-id-type="pmid">11809922</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Chung</surname><given-names>M.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>H. J.</given-names></name></person-group><article-title>The effects of <italic>Irvingia gabonensis</italic> seed extract supplementation on anthropometric and cardiovascular outcomes: a systematic review and meta-analysis</article-title><source><italic toggle="yes">Journal of the American College of Nutrition</italic></source><year>2020</year><volume>39</volume><issue>5</issue><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1080/07315724.2019.1691956</pub-id><pub-id pub-id-type="pmid">31855111</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuyooro</surname><given-names>S. E.</given-names></name><name><surname>Abam</surname><given-names>E. O.</given-names></name><name><surname>Agbede</surname><given-names>E. B.</given-names></name></person-group><article-title>Hypolipidemic effects of <italic>Irvingia gabonensis</italic> - supplemented diets in male Albino rats</article-title><source><italic toggle="yes">Biochemistry &#x00026; Analytical Biochemistry</italic></source><year>2017</year><volume>6</volume><issue>2, article 1000316</issue></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatoki</surname><given-names>J. O.</given-names></name><name><surname>Adedosu</surname><given-names>O. T.</given-names></name><name><surname>Afolabi</surname><given-names>O. K.</given-names></name><etal/></person-group><article-title>Dyslipidemic effect of doxorubicin and etoposide: a predisposing factor for the antineoplastic drugs-induced cardiovascular diseases</article-title><source><italic toggle="yes">Research &#x00026; Reviews: Journal of Pharmacology and Toxicological Studies</italic></source><year>2018</year><volume>6</volume><issue>1</issue><fpage>34</fpage><lpage>42</lpage></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mentoor</surname><given-names>I.</given-names></name><name><surname>Nell</surname><given-names>T.</given-names></name><name><surname>Emjedi</surname><given-names>Z.</given-names></name><name><surname>van Jaarsveld</surname><given-names>P. J.</given-names></name><name><surname>de Jager</surname><given-names>L.</given-names></name><name><surname>Engelbrecht</surname><given-names>A. M.</given-names></name></person-group><article-title>Decreased efficacy of doxorubicin corresponds with modifications in lipid metabolism markers and fatty acid profiles in breast tumors from obese vs. lean mice</article-title><source><italic toggle="yes">Frontiers in Oncology</italic></source><year>2020</year><volume>10</volume><fpage>p. 306</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.00306</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arunachalam</surname><given-names>S.</given-names></name><name><surname>Tirupathi Pichiah</surname><given-names>P. B.</given-names></name><name><surname>Achiraman</surname><given-names>S.</given-names></name></person-group><article-title>Doxorubicin treatment inhibits PPAR<italic>&#x003b3;</italic> and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models</article-title><source><italic toggle="yes">FEBS Letters</italic></source><year>2013</year><volume>587</volume><issue>2</issue><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2012.11.019</pub-id><pub-id pub-id-type="other">2-s2.0-84872115843</pub-id><?supplied-pmid 23219922?><pub-id pub-id-type="pmid">23219922</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngondi</surname><given-names>J. L.</given-names></name><name><surname>Oben</surname><given-names>J. E.</given-names></name><name><surname>Minka</surname><given-names>S. R.</given-names></name></person-group><article-title>The effect of <italic>Irvingia gabonensis</italic> seeds on body weight and blood lipids of obese subjects in Cameroon</article-title><source><italic toggle="yes">Lipids in Health and Disease</italic></source><year>2005</year><volume>4</volume><issue>1</issue><fpage>p. 12</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-4-12</pub-id><pub-id pub-id-type="other">2-s2.0-23244455150</pub-id><pub-id pub-id-type="pmid">15916709</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oben</surname><given-names>J. E.</given-names></name><name><surname>Ngondi</surname><given-names>J. L.</given-names></name><name><surname>Blum</surname><given-names>K.</given-names></name></person-group><article-title>Inhibition of <italic>Irvingia gabonensis</italic> seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene</article-title><source><italic toggle="yes">Lipids in Health and Disease</italic></source><year>2008</year><volume>7</volume><issue>1</issue><fpage>p. 44</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-7-44</pub-id><pub-id pub-id-type="other">2-s2.0-57049130437</pub-id><pub-id pub-id-type="pmid">19014517</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngondi</surname><given-names>J. L.</given-names></name><name><surname>Etoundi</surname><given-names>B. C.</given-names></name><name><surname>Nyangono</surname><given-names>C. B.</given-names></name><name><surname>Mbofung</surname><given-names>C. M. F.</given-names></name><name><surname>Oben</surname><given-names>J. E.</given-names></name></person-group><article-title>IGOB131, a novel seed extract of the West African plant <italic>Irvingia gabonensis</italic>, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation</article-title><source><italic toggle="yes">Lipids in Health and Disease</italic></source><year>2009</year><volume>8</volume><issue>1</issue><fpage>p. 7</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-8-7</pub-id><pub-id pub-id-type="other">2-s2.0-61849167344</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onakpoya</surname><given-names>I.</given-names></name><name><surname>Davies</surname><given-names>L.</given-names></name><name><surname>Posadzki</surname><given-names>P.</given-names></name><name><surname>Ernst</surname><given-names>E.</given-names></name></person-group><article-title>The efficacy of <italic>Irvingia gabonensis</italic> supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials</article-title><source><italic toggle="yes">Journal of Dietary Supplements</italic></source><year>2013</year><volume>10</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.3109/19390211.2012.760508</pub-id><pub-id pub-id-type="other">2-s2.0-84874233116</pub-id><?supplied-pmid 23419021?><pub-id pub-id-type="pmid">23419021</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Nam</surname><given-names>D. E.</given-names></name><name><surname>Kim</surname><given-names>O. K.</given-names></name><name><surname>Shim</surname><given-names>T. J.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group><article-title>Anti-obesity effects of African mango (<italic>Irvingia gabonesis</italic>, IGOB 131TM) extract in leptin-deficient obese mice</article-title><source><italic toggle="yes">Journal of the Korean Society of Food Science and Nutrition</italic></source><year>2014</year><volume>43</volume><issue>10</issue><fpage>1477</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.3746/jkfn.2014.43.10.1477</pub-id><pub-id pub-id-type="other">2-s2.0-84908554308</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azantsa</surname><given-names>B.</given-names></name><name><surname>Kuate</surname><given-names>D.</given-names></name><name><surname>Chakokam</surname><given-names>R.</given-names></name><name><surname>Paka</surname><given-names>G.</given-names></name><name><surname>Bartholomew</surname><given-names>B.</given-names></name><name><surname>Nash</surname><given-names>R.</given-names></name></person-group><article-title>The effect of extracts of <italic>Irvingia gabonensis</italic> (IGOB131) and <italic>Dichrostachys glomerata</italic> (Dyglomera&#x02122;) on body weight and lipid parameters of healthy overweight participants</article-title><source><italic toggle="yes">Functional Foods in Health and Disease</italic></source><year>2015</year><volume>5</volume><issue>6</issue><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.31989/ffhd.v5i6.184</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>S.</given-names></name><name><surname>Nithya</surname><given-names>S.</given-names></name><name><surname>Srinithya</surname><given-names>B.</given-names></name><name><surname>Meenakshi</surname><given-names>S. M.</given-names></name></person-group><article-title>Review of medicinal plants for anti-obesity activity</article-title><source><italic toggle="yes">Translational Biomedicine</italic></source><year>2015</year><volume>6</volume><issue>3</issue><pub-id pub-id-type="doi">10.21767/2172-0479.100021</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>Y.</given-names></name><name><surname>Niki</surname><given-names>E.</given-names></name></person-group><article-title>Antioxidant effects of phytosterol and its components</article-title><source><italic toggle="yes">Journal of Nutritional Science and Vitaminology</italic></source><year>2003</year><volume>49</volume><issue>4</issue><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.3177/jnsv.49.277</pub-id><pub-id pub-id-type="other">2-s2.0-0141814690</pub-id><pub-id pub-id-type="pmid">14598915</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meguro</surname><given-names>S.</given-names></name><name><surname>Higashi</surname><given-names>K.</given-names></name><name><surname>Hase</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Solubilization of phytosterols in diacylglycerol versus triacylglycerol improves the serum cholesterol-lowering effect</article-title><source><italic toggle="yes">European Journal of Clinical Nutrition</italic></source><year>2001</year><volume>55</volume><issue>7</issue><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/sj.ejcn.1601173</pub-id><pub-id pub-id-type="other">2-s2.0-0034955211</pub-id><?supplied-pmid 11464223?><pub-id pub-id-type="pmid">11464223</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demonty</surname><given-names>I.</given-names></name><name><surname>Ras</surname><given-names>R. T.</given-names></name><name><surname>van der Knaap</surname><given-names>H. C. M.</given-names></name><etal/></person-group><article-title>Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake</article-title><source><italic toggle="yes">The Journal of Nutrition</italic></source><year>2009</year><volume>139</volume><issue>2</issue><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.3945/jn.108.095125</pub-id><pub-id pub-id-type="other">2-s2.0-60249092628</pub-id><?supplied-pmid 19091798?><pub-id pub-id-type="pmid">19091798</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ras</surname><given-names>R. T.</given-names></name><name><surname>Geleijnse</surname><given-names>J. M.</given-names></name><name><surname>Trautwein</surname><given-names>E. A.</given-names></name></person-group><article-title>LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies</article-title><source><italic toggle="yes">The British Journal of Nutrition</italic></source><year>2014</year><volume>112</volume><issue>2</issue><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1017/S0007114514000750</pub-id><pub-id pub-id-type="other">2-s2.0-84903200069</pub-id><?supplied-pmid 24780090?><pub-id pub-id-type="pmid">24780090</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trautwein</surname><given-names>E.</given-names></name><name><surname>Vermeer</surname><given-names>M.</given-names></name><name><surname>Hiemstra</surname><given-names>H.</given-names></name><name><surname>Ras</surname><given-names>R.</given-names></name></person-group><article-title>LDL-cholesterol lowering of plant sterols and stanols - which factors influence their efficacy?</article-title><source><italic toggle="yes">Nutrients</italic></source><year>2018</year><volume>10</volume><issue>9, article 1262</issue><pub-id pub-id-type="doi">10.3390/nu10091262</pub-id><pub-id pub-id-type="other">2-s2.0-85053080678</pub-id><?supplied-pmid 30205492?><pub-id pub-id-type="pmid">30205492</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Long</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>R.</given-names></name></person-group><article-title>Effect of <italic>&#x003b2;</italic>-sitosterol self-microemulsion and <italic>&#x003b2;</italic>-sitosterol ester with linoleic acid on lipid-lowering in hyperlipidemic mice</article-title><source><italic toggle="yes">Lipids in Health and Disease</italic></source><year>2019</year><volume>18</volume><issue>1</issue><fpage>p. 157</fpage><pub-id pub-id-type="doi">10.1186/s12944-019-1096-2</pub-id><pub-id pub-id-type="other">2-s2.0-85069947054</pub-id><?supplied-pmid 31351498?><pub-id pub-id-type="pmid">31351498</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Lafi</surname><given-names>S.</given-names></name><name><surname>Rayan</surname><given-names>M.</given-names></name><name><surname>Masalha</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phytochemical composition and biological activities of wild <italic>Scolymus maculatus</italic> L.</article-title><source><italic toggle="yes">Medicine</italic></source><year>2019</year><volume>6</volume><issue>2</issue><fpage>p. 53</fpage><pub-id pub-id-type="doi">10.3390/medicines6020053</pub-id><?supplied-pmid 31052242?><pub-id pub-id-type="pmid">31052242</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleem</surname><given-names>M.</given-names></name><name><surname>Murtaza</surname><given-names>I.</given-names></name><name><surname>Tarapore</surname><given-names>R. S.</given-names></name><etal/></person-group><article-title>Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling</article-title><source><italic toggle="yes">Carcinogenesis</italic></source><year>2009</year><volume>30</volume><issue>5</issue><fpage>808</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp044</pub-id><pub-id pub-id-type="other">2-s2.0-65449167684</pub-id><?supplied-pmid 19233958?><pub-id pub-id-type="pmid">19233958</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L. S.</given-names></name><name><surname>Wee</surname><given-names>W.</given-names></name><name><surname>Siong</surname><given-names>J. Y. F.</given-names></name><name><surname>Syamsumir</surname><given-names>D. F.</given-names></name></person-group><article-title>Characterization of anticancer, antimicrobial, antioxidant properties and chemical compositions of <italic>Peperomia pellucida</italic> leaf extract</article-title><source><italic toggle="yes">Acta Medica Iranica</italic></source><year>2011</year><volume>49</volume><issue>10</issue><fpage>670</fpage><lpage>674</lpage><?supplied-pmid 22071643?><pub-id pub-id-type="pmid">22071643</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Cho</surname><given-names>S. K.</given-names></name></person-group><article-title>Phytol induces apoptosis and ROS mediated protective autophagy in human gastric adenocarcinoma AGS cells</article-title><source><italic toggle="yes">Biochemistry and Analytical Biochemistry</italic></source><year>2015</year><volume>4</volume><fpage>p. 211</fpage></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amarowicz</surname><given-names>R.</given-names></name></person-group><article-title>Squalene: a natural antioxidant?</article-title><source><italic toggle="yes">European Journal of Lipid Science and Technology</italic></source><year>2009</year><volume>111</volume><issue>5</issue><fpage>411</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1002/ejlt.200900102</pub-id><pub-id pub-id-type="other">2-s2.0-67449147095</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.-K.</given-names></name><name><surname>Karadeniz</surname><given-names>F.</given-names></name></person-group><article-title>Biological importance and applications of squalene and squalane</article-title><source><italic toggle="yes">Advances in Food and Nutrition Research</italic></source><year>2012</year><volume>65</volume><fpage>223</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-416003-3.00014-7</pub-id><pub-id pub-id-type="other">2-s2.0-84863164261</pub-id><pub-id pub-id-type="pmid">22361190</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Arfa</surname><given-names>A.</given-names></name><name><surname>Combes</surname><given-names>S.</given-names></name><name><surname>Preziosi-Belloy</surname><given-names>L.</given-names></name><name><surname>Gontard</surname><given-names>N.</given-names></name><name><surname>Chalier</surname><given-names>P.</given-names></name></person-group><article-title>Antimicrobial activity of carvacrol related to its chemical structure</article-title><source><italic toggle="yes">Letters in Applied Microbiology</italic></source><year>2006</year><volume>43</volume><issue>2</issue><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1111/j.1472-765X.2006.01938.x</pub-id><pub-id pub-id-type="other">2-s2.0-33745882992</pub-id><pub-id pub-id-type="pmid">16869897</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzalevskaya</surname><given-names>E. N.</given-names></name><name><surname>Miroshnichenko</surname><given-names>L. A.</given-names></name><name><surname>Nikolaevskii</surname><given-names>V. A.</given-names></name><etal/></person-group><article-title>Squalene: physiological and pharmacological properties</article-title><source><italic toggle="yes">Eksperimental'naia i Klinicheskaia Farmakologiia</italic></source><year>2015</year><volume>78</volume><issue>6</issue><fpage>30</fpage><lpage>36</lpage><?supplied-pmid 26292512?><pub-id pub-id-type="pmid">26292512</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkata Raman</surname><given-names>B.</given-names></name><name><surname>Samuel</surname><given-names>L. A.</given-names></name><name><surname>Saradhi</surname><given-names>M. P.</given-names></name><etal/></person-group><article-title>Antibacterial, antioxidant activity and GC-MS analysis of <italic>Eupatorium odoratum</italic></article-title><source><italic toggle="yes">Asian Journal of Pharmaceutical and Clinical Research</italic></source><year>2012</year><volume>5</volume><issue>2</issue><fpage>99</fpage><lpage>106</lpage></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swamy</surname><given-names>M. K.</given-names></name><name><surname>Arumugam</surname><given-names>G.</given-names></name><name><surname>Kaur</surname><given-names>R.</given-names></name><name><surname>Ghasemzadeh</surname><given-names>A.</given-names></name><name><surname>Yusoff</surname><given-names>M. M.</given-names></name><name><surname>Sinniah</surname><given-names>U. R.</given-names></name></person-group><article-title>GC-MS based metabolite profiling, antioxidant and antimicrobial properties of different solvent extracts of MalaysianPlectranthus amboinicusLeaves</article-title><source><italic toggle="yes">Evidence-Based Complementary and Alternative Medicine</italic></source><year>2017</year><volume>2017</volume><fpage>10</fpage><pub-id pub-id-type="publisher-id">1517683</pub-id><pub-id pub-id-type="doi">10.1155/2017/1517683</pub-id><pub-id pub-id-type="other">2-s2.0-85017180287</pub-id><?supplied-pmid 28424737?><pub-id pub-id-type="pmid">28424737</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordier</surname><given-names>W.</given-names></name><name><surname>Steenkamp</surname><given-names>V.</given-names></name></person-group><article-title>Herbal remedies affecting coagulation: a review</article-title><source><italic toggle="yes">Pharmaceutical Biology</italic></source><year>2012</year><volume>50</volume><issue>4</issue><fpage>443</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.3109/13880209.2011.611145</pub-id><pub-id pub-id-type="other">2-s2.0-84858004528</pub-id><pub-id pub-id-type="pmid">22136282</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmud</surname><given-names>S.</given-names></name><name><surname>Akhter</surname><given-names>S.</given-names></name><name><surname>Rahman</surname><given-names>M. A.</given-names></name><etal/></person-group><article-title>Antithrombotic effects of five organic extracts of Bangladeshi plants in vitro and mechanisms in in silico models</article-title><source><italic toggle="yes">eCAM</italic></source><year>2015</year><volume>2015, article 782742</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2015/782742</pub-id><pub-id pub-id-type="other">2-s2.0-84930673826</pub-id><?supplied-pmid 26075001?><pub-id pub-id-type="pmid">26075001</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thom</surname><given-names>V. T.</given-names></name><name><surname>Tung</surname><given-names>N. H.</given-names></name><name><surname>van Diep</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Antithrombotic activity and saponin composition of the roots of Panax <italic>bipinnatifidus Seem.</italic> growing in Vietnam</article-title><source><italic toggle="yes">Pharmacognosy Research</italic></source><year>2018</year><volume>10</volume><issue>4</issue><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.4103/pr.pr_58_18</pub-id><pub-id pub-id-type="other">2-s2.0-85055795534</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gogoi</surname><given-names>D.</given-names></name><name><surname>Pal</surname><given-names>A.</given-names></name><name><surname>Chattopadhyay</surname><given-names>P.</given-names></name><name><surname>Paul</surname><given-names>S.</given-names></name><name><surname>Deka</surname><given-names>R. C.</given-names></name><name><surname>Mukherjee</surname><given-names>A. K.</given-names></name></person-group><article-title>First report of plant-derived <italic>&#x003b2;</italic>-sitosterol with antithrombotic, <italic>in vivo</italic> anticoagulant, and thrombus-preventing activities in a mouse model</article-title><source><italic toggle="yes">Journal of Natural Products</italic></source><year>2018</year><volume>81</volume><issue>11</issue><fpage>2521</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.8b00574</pub-id><pub-id pub-id-type="other">2-s2.0-85057095319</pub-id><?supplied-pmid 30406661?><pub-id pub-id-type="pmid">30406661</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salunkhe</surname><given-names>P. S.</given-names></name><name><surname>Patil</surname><given-names>S. D.</given-names></name><name><surname>Dhande</surname><given-names>S. R.</given-names></name></person-group><article-title>Anti-thrombotic activity of isolated <italic>&#x003b2;</italic>-sitosterol from roots of <italic>Hemidesmus indicus</italic> Linn. in rat model</article-title><source><italic toggle="yes">Journal of Pharmacognosy and Phytochemistry</italic></source><year>2018</year><volume>7</volume><issue>SP6</issue><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.22271/phyto.2018.v7.isp6.1.03</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>GC-MS analysis showing the relative abundance of the secondary metabolites in <italic>IGESE.</italic></p></caption><graphic xlink:href="OMCL2020-1602816.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>A cross-sectional representative of 15&#x02009;mg/kg of DOX-only intoxicated rat cardiac tissue showing antemortem coronary artery microthrombi and congested cardiomyocytes suggestive of coronary intravascular thrombosis (&#x000d7;400 magnification, Hematoxylin and Eosin stain).</p></caption><graphic xlink:href="OMCL2020-1602816.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>A cross-sectional representative of normal rat cardiac tissue showing normal cardiac histoarchitecture (&#x000d7;400 magnification, Hematoxylin and Eosin stain).</p></caption><graphic xlink:href="OMCL2020-1602816.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>A cross-sectional representative of 200&#x02009;mg/kg/day of <italic>IGESE</italic>-only pretreated rat cardiac tissue showing normal cardiac histoarchitecture (&#x000d7;400 magnification, Hematoxylin and Eosin stain).</p></caption><graphic xlink:href="OMCL2020-1602816.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>A cross-sectional representative of 200&#x02009;mg/kg of <italic>IGESE</italic> pretreated, DOX intoxicated rat cardiac tissue showing mildly congested cardiomyocytes (&#x000d7;400 magnification, Hematoxylin and Eosin stain).</p></caption><graphic xlink:href="OMCL2020-1602816.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>A cross-sectional representative of 400&#x02009;mg/kg of <italic>IGESE</italic> pretreated, DOX intoxicated rat cardiac tissue showing normal cardiac histoarchitecture (&#x000d7;400 magnification, Hematoxylin and Eosin stain).</p></caption><graphic xlink:href="OMCL2020-1602816.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>A cross-sectional representative of 100&#x02009;mg/kg/day of IGESE-pretreated, DOX-intoxicated cardiac tissue showing mild-to-moderate vascular congestion but normal myocardiocytes (&#x000d7;400 magnification, Hematoxylin-Eosin stain).</p></caption><graphic xlink:href="OMCL2020-1602816.007"/></fig><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>A cross-sectional representative of 20&#x02009;mg/kg/day of vitamin C pretreated, DOX intoxicated rat cardiac tissue showing mild-to-moderate antemortem coronary artery thrombus and normal cardiomyocytes suggestive of coronary intravascular thrombosis (&#x000d7;400 magnification, Hematoxylin and Eosin stain).</p></caption><graphic xlink:href="OMCL2020-1602816.008"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Group treatment of rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="center" rowspan="1" colspan="1">Treatments</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group I</td><td align="center" rowspan="1" colspan="1">10&#x02009;ml/kg of distilled water given <italic>p.o.</italic> for 10 days +1&#x02009;ml/kg of 0.9% normal saline given <italic>i.p.</italic> on day 11</td></tr><tr><td align="left" rowspan="1" colspan="1">Group II</td><td align="center" rowspan="1" colspan="1">200&#x02009;mg/kg/day of <italic>IGESE</italic> in 5% DMSO-distilled water given <italic>p.o.</italic> for 10 days +1&#x02009;ml/kg of 0.9% normal saline given <italic>i.p.</italic> on day 11</td></tr><tr><td align="left" rowspan="1" colspan="1">Group III</td><td align="center" rowspan="1" colspan="1">10&#x02009;ml/kg/day of distilled water given <italic>p.o.</italic> for 10 days +15&#x02009;mg/kg of doxorubicin hydrochloride in 0.9% normal saline given <italic>i.p.</italic> on day 11</td></tr><tr><td align="left" rowspan="1" colspan="1">Group IV</td><td align="center" rowspan="1" colspan="1">20&#x02009;mg/kg/day of Vit. C dissolved in 5% DMSO-distilled water given <italic>p.o.</italic> for 10 days +15&#x02009;mg/kg of doxorubicin hydrochloride in 0.9% normal saline given <italic>i.p.</italic> on day 11</td></tr><tr><td align="left" rowspan="1" colspan="1">Group V</td><td align="center" rowspan="1" colspan="1">100&#x02009;mg/kg/day of <italic>IGESE</italic> dissolved in 5% DMSO-distilled water given <italic>p.o.</italic> for 10 days +15&#x02009;mg/kg of doxorubicin hydrochloride in 0.9% normal saline given <italic>i.p.</italic> on day 11</td></tr><tr><td align="left" rowspan="1" colspan="1">Group VI</td><td align="center" rowspan="1" colspan="1">200&#x02009;mg/kg/day of <italic>IGESE</italic> dissolved in 5% DMSO-distilled water given <italic>p.o.</italic> for 10 days +15&#x02009;mg/kg of doxorubicin hydrochloride in 0.9% normal saline given <italic>i.p.</italic> on day 11</td></tr><tr><td align="left" rowspan="1" colspan="1">Group VII</td><td align="center" rowspan="1" colspan="1">400&#x02009;mg/kg/day of <italic>IGESE</italic> dissolved in 5% DMSO-distilled water given <italic>p.o.</italic> for 10 days +15&#x02009;mg/kg of doxorubicin hydrochloride in 0.9% normal saline given <italic>i.p.</italic> on day 11</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Quantitative analysis of the secondary metabolites in <italic>IGESE</italic> (mg/100&#x02009;g of dry extract sample).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Secondary metabolite</th><th align="center" rowspan="1" colspan="1">Quantity (mg/100&#x02009;g of dry extract)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Flavonoids</td><td align="center" rowspan="1" colspan="1">18.19 &#x000b1; 0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Alkaloids</td><td align="center" rowspan="1" colspan="1">50.51 &#x000b1; 0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Reducing sugar</td><td align="center" rowspan="1" colspan="1">65.64 &#x000b1; 0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Phenols</td><td align="center" rowspan="1" colspan="1">57.18 &#x000b1; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Steroids</td><td align="center" rowspan="1" colspan="1">47.47 &#x000b1; 0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Tannin</td><td align="center" rowspan="1" colspan="1">41.60 &#x000b1; 0.03</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Quantitative analysis of the secondary metabolites (PhytoScan) of <italic>Irvingia gabonensis</italic> ethanol seed extract (<italic>IGESE</italic>) using gas chromatography-mass spectrometry.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Pk#</th><th align="center" rowspan="1" colspan="1">RT</th><th align="center" rowspan="1" colspan="1">Area (%)</th><th align="center" rowspan="1" colspan="1">Library/IDRef#</th><th align="center" rowspan="1" colspan="1">CAS#</th><th align="center" rowspan="1" colspan="1">Quality (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1.</td><td align="center" rowspan="1" colspan="1">4.069</td><td align="center" rowspan="1" colspan="1">0.1378</td><td align="center" rowspan="1" colspan="1">Ethanol, 2-(ethylamino)-</td><td align="center" rowspan="1" colspan="1">000110-73-6</td><td align="center" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">2.</td><td align="center" rowspan="1" colspan="1">4.906</td><td align="center" rowspan="1" colspan="1">0.0411</td><td align="center" rowspan="1" colspan="1">Oxime-, methoxy-phenyl-</td><td align="center" rowspan="1" colspan="1">1000222-86-6</td><td align="center" rowspan="1" colspan="1">91</td></tr><tr><td align="left" rowspan="1" colspan="1">3.</td><td align="center" rowspan="1" colspan="1">5.137</td><td align="center" rowspan="1" colspan="1">0.1764</td><td align="center" rowspan="1" colspan="1">1,2-Cyclopentanedione</td><td align="center" rowspan="1" colspan="1">003008-40-0</td><td align="center" rowspan="1" colspan="1">78</td></tr><tr><td align="left" rowspan="1" colspan="1">4.</td><td align="center" rowspan="1" colspan="1">5.455</td><td align="center" rowspan="1" colspan="1">0.0811</td><td align="center" rowspan="1" colspan="1">Cyclotetrasiloxane, octamethyl-</td><td align="center" rowspan="1" colspan="1">000556-67-2</td><td align="center" rowspan="1" colspan="1">83</td></tr><tr><td align="left" rowspan="1" colspan="1">5.</td><td align="center" rowspan="1" colspan="1">5.721</td><td align="center" rowspan="1" colspan="1">0.8170</td><td align="center" rowspan="1" colspan="1">Phenol</td><td align="center" rowspan="1" colspan="1">000108-95-2</td><td align="center" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1">6.</td><td align="center" rowspan="1" colspan="1">5.905</td><td align="center" rowspan="1" colspan="1">0.1070</td><td align="center" rowspan="1" colspan="1">Phenol</td><td align="center" rowspan="1" colspan="1">000108-95-2</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">7.</td><td align="center" rowspan="1" colspan="1">8.291</td><td align="center" rowspan="1" colspan="1">0.1399</td><td align="center" rowspan="1" colspan="1">Z,Z-7,11-Hexadecadien-1-ol</td><td align="center" rowspan="1" colspan="1">1000131-01-4</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">8.</td><td align="center" rowspan="1" colspan="1">8.458</td><td align="center" rowspan="1" colspan="1">0.0616</td><td align="center" rowspan="1" colspan="1">Cyclotetrasiloxane, octamethyl-</td><td align="center" rowspan="1" colspan="1">000556-67-2</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td align="left" rowspan="1" colspan="1">9.</td><td align="center" rowspan="1" colspan="1">10.387</td><td align="center" rowspan="1" colspan="1">0.0843</td><td align="center" rowspan="1" colspan="1">Naphthalen-4a,8a-imine, octahydro-</td><td align="center" rowspan="1" colspan="1">005735-21-7</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">10.</td><td align="center" rowspan="1" colspan="1">10.503</td><td align="center" rowspan="1" colspan="1">0.7119</td><td align="center" rowspan="1" colspan="1">Pyrrolidine, 1-(1-cyclohexen-1-yl)-</td><td align="center" rowspan="1" colspan="1">001125-99-1</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">11.</td><td align="center" rowspan="1" colspan="1">11.288</td><td align="center" rowspan="1" colspan="1">0.1380</td><td align="center" rowspan="1" colspan="1">Cycloheptasiloxane, tetradecamethyl-</td><td align="center" rowspan="1" colspan="1">000107-50-6</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">12.</td><td align="center" rowspan="1" colspan="1">12.137</td><td align="center" rowspan="1" colspan="1">0.4489</td><td align="center" rowspan="1" colspan="1">4-Methyl-2,5-dimethoxybenzaldehyde</td><td align="center" rowspan="1" colspan="1">004925-88-6</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">13.</td><td align="center" rowspan="1" colspan="1">13.125</td><td align="center" rowspan="1" colspan="1">5.0814</td><td align="center" rowspan="1" colspan="1">Undecanoic acid</td><td align="center" rowspan="1" colspan="1">000112-37-8</td><td align="center" rowspan="1" colspan="1">53</td></tr><tr><td align="left" rowspan="1" colspan="1">14.</td><td align="center" rowspan="1" colspan="1">14.516</td><td align="center" rowspan="1" colspan="1">3.7713</td><td align="center" rowspan="1" colspan="1">Neophytadiene</td><td align="center" rowspan="1" colspan="1">000504-96-1</td><td align="center" rowspan="1" colspan="1">89</td></tr><tr><td align="left" rowspan="1" colspan="1">15.</td><td align="center" rowspan="1" colspan="1">15.088</td><td align="center" rowspan="1" colspan="1">27.0790</td><td align="center" rowspan="1" colspan="1">4,6-di-O-methyl-alpha-d-galactose</td><td align="center" rowspan="1" colspan="1">024462-98-4</td><td align="center" rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1">16.</td><td align="center" rowspan="1" colspan="1">15.695</td><td align="center" rowspan="1" colspan="1">5.5072</td><td align="center" rowspan="1" colspan="1">n-Hexadecanoic acid</td><td align="center" rowspan="1" colspan="1">000057-10-3</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">17.</td><td align="center" rowspan="1" colspan="1">15.816</td><td align="center" rowspan="1" colspan="1">2.5123</td><td align="center" rowspan="1" colspan="1">Hexadecanoic acid, ethyl ester</td><td align="center" rowspan="1" colspan="1">000628-97-7</td><td align="center" rowspan="1" colspan="1">98</td></tr><tr><td align="left" rowspan="1" colspan="1">18.</td><td align="center" rowspan="1" colspan="1">16.116</td><td align="center" rowspan="1" colspan="1">0.0474</td><td align="center" rowspan="1" colspan="1">Heptadecanoic acid</td><td align="center" rowspan="1" colspan="1">000506-12-7</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">19.</td><td align="center" rowspan="1" colspan="1">16.595</td><td align="center" rowspan="1" colspan="1">0.1190</td><td align="center" rowspan="1" colspan="1">Heptadecanoic acid, ethyl ester</td><td align="center" rowspan="1" colspan="1">014010-23-2</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">20.</td><td align="center" rowspan="1" colspan="1">16.774</td><td align="center" rowspan="1" colspan="1">3.8358</td><td align="center" rowspan="1" colspan="1">Phytol</td><td align="center" rowspan="1" colspan="1">000150-86-7</td><td align="center" rowspan="1" colspan="1">91</td></tr><tr><td align="left" rowspan="1" colspan="1">21.</td><td align="center" rowspan="1" colspan="1">17.063</td><td align="center" rowspan="1" colspan="1">4.8375</td><td align="center" rowspan="1" colspan="1">9,12,15-Octadecatrienoic acid, (Z,Z,Z)-</td><td align="center" rowspan="1" colspan="1">000463-40-1</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">22.</td><td align="center" rowspan="1" colspan="1">17.185</td><td align="center" rowspan="1" colspan="1">3.6541</td><td align="center" rowspan="1" colspan="1">Ethyl 9,12,15-octadecatrienoate</td><td align="center" rowspan="1" colspan="1">1000336-77-4</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">23.</td><td align="center" rowspan="1" colspan="1">17.352</td><td align="center" rowspan="1" colspan="1">0.9067</td><td align="center" rowspan="1" colspan="1">Octadecanoic acid, ethyl ester</td><td align="center" rowspan="1" colspan="1">000111-61-5</td><td align="center" rowspan="1" colspan="1">98</td></tr><tr><td align="left" rowspan="1" colspan="1">24.</td><td align="center" rowspan="1" colspan="1">17.508</td><td align="center" rowspan="1" colspan="1">0.3478</td><td align="center" rowspan="1" colspan="1">14-Pentadecenoic acid</td><td align="center" rowspan="1" colspan="1">017351-34-7</td><td align="center" rowspan="1" colspan="1">86</td></tr><tr><td align="left" rowspan="1" colspan="1">25.</td><td align="center" rowspan="1" colspan="1">18.420</td><td align="center" rowspan="1" colspan="1">0.1330</td><td align="center" rowspan="1" colspan="1">Bicyclo[3.1.1]heptan-2-one, 6,6-dimethyl-</td><td align="center" rowspan="1" colspan="1">024903-95-5</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">26.</td><td align="center" rowspan="1" colspan="1">18.605</td><td align="center" rowspan="1" colspan="1">0.0633</td><td align="center" rowspan="1" colspan="1">Cis-vaccenic acid</td><td align="center" rowspan="1" colspan="1">000506-17-2</td><td align="center" rowspan="1" colspan="1">91</td></tr><tr><td align="left" rowspan="1" colspan="1">27.</td><td align="center" rowspan="1" colspan="1">18.761</td><td align="center" rowspan="1" colspan="1">0.1262</td><td align="center" rowspan="1" colspan="1">Heptadecanoic acid, ethyl ester</td><td align="center" rowspan="1" colspan="1">014010-23-2</td><td align="center" rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1">28.</td><td align="center" rowspan="1" colspan="1">19.264</td><td align="center" rowspan="1" colspan="1">0.0555</td><td align="center" rowspan="1" colspan="1">Cyclopentadecanone, 2-hydroxy-</td><td align="center" rowspan="1" colspan="1">004727-18-8</td><td align="center" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1">29.</td><td align="center" rowspan="1" colspan="1">19.425</td><td align="center" rowspan="1" colspan="1">0.173</td><td align="center" rowspan="1" colspan="1">Ethyl 9-hexadecenoate</td><td align="center" rowspan="1" colspan="1">054546-22-4</td><td align="center" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">30.</td><td align="center" rowspan="1" colspan="1">19.599</td><td align="center" rowspan="1" colspan="1">0.594</td><td align="center" rowspan="1" colspan="1">Octadecanoic acid, 2,3-dihydroxypropyl ester</td><td align="center" rowspan="1" colspan="1">000123-94-4</td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="left" rowspan="1" colspan="1">31.</td><td align="center" rowspan="1" colspan="1">19.818</td><td align="center" rowspan="1" colspan="1">0.0961</td><td align="center" rowspan="1" colspan="1">1,4-benzenedicarboxylic acid, mono(1-methylethyl) ester</td><td align="center" rowspan="1" colspan="1">1000400-56-6</td><td align="center" rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1">32.</td><td align="center" rowspan="1" colspan="1">19.934</td><td align="center" rowspan="1" colspan="1">0.0379</td><td align="center" rowspan="1" colspan="1">Cis-9-tetradecenoic acid, heptyl ester</td><td align="center" rowspan="1" colspan="1">1000405-20-8</td><td align="center" rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1">33.</td><td align="center" rowspan="1" colspan="1">20.078</td><td align="center" rowspan="1" colspan="1">0.1537</td><td align="center" rowspan="1" colspan="1">Docosanoic acid, ethyl ester</td><td align="center" rowspan="1" colspan="1">005908-87-2</td><td align="center" rowspan="1" colspan="1">93</td></tr><tr><td align="left" rowspan="1" colspan="1">34.</td><td align="center" rowspan="1" colspan="1">20.251</td><td align="center" rowspan="1" colspan="1">0.0452</td><td align="center" rowspan="1" colspan="1">18-nonadecenoic acid</td><td align="center" rowspan="1" colspan="1">076998-87-3</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td align="left" rowspan="1" colspan="1">35.</td><td align="center" rowspan="1" colspan="1">20.742</td><td align="center" rowspan="1" colspan="1">0.3606</td><td align="center" rowspan="1" colspan="1">1,3,12-nonadecatriene</td><td align="center" rowspan="1" colspan="1">1000131-11-1</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td align="left" rowspan="1" colspan="1">36.</td><td align="center" rowspan="1" colspan="1">20.887</td><td align="center" rowspan="1" colspan="1">0.1046</td><td align="center" rowspan="1" colspan="1">2-methyl-Z,Z-3,13-octadecadienol</td><td align="center" rowspan="1" colspan="1">1000130-90-5</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">37.</td><td align="center" rowspan="1" colspan="1">21.510</td><td align="center" rowspan="1" colspan="1">0.2565</td><td align="center" rowspan="1" colspan="1">Squalene</td><td align="center" rowspan="1" colspan="1">000111-02-4</td><td align="center" rowspan="1" colspan="1">90</td></tr><tr><td align="left" rowspan="1" colspan="1">38.</td><td align="center" rowspan="1" colspan="1">22.844</td><td align="center" rowspan="1" colspan="1">0.3462</td><td align="center" rowspan="1" colspan="1">
<italic>&#x003b3;</italic>-Tocopherol</td><td align="center" rowspan="1" colspan="1">007616-22-0</td><td align="center" rowspan="1" colspan="1">98</td></tr><tr><td align="left" rowspan="1" colspan="1">39.</td><td align="center" rowspan="1" colspan="1">23.052</td><td align="center" rowspan="1" colspan="1">0.6599</td><td align="center" rowspan="1" colspan="1">Triacontyl acetate</td><td align="center" rowspan="1" colspan="1">041755-58-2</td><td align="center" rowspan="1" colspan="1">95</td></tr><tr><td align="left" rowspan="1" colspan="1">40.</td><td align="center" rowspan="1" colspan="1">23.341</td><td align="center" rowspan="1" colspan="1">2.9085</td><td align="center" rowspan="1" colspan="1">Vitamin E</td><td align="center" rowspan="1" colspan="1">000059-02-9</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">41.</td><td align="center" rowspan="1" colspan="1">24.040</td><td align="center" rowspan="1" colspan="1">1.3362</td><td align="center" rowspan="1" colspan="1">Campesterol</td><td align="center" rowspan="1" colspan="1">000474-62-4</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">42.</td><td align="center" rowspan="1" colspan="1">24.277</td><td align="center" rowspan="1" colspan="1">3.0258</td><td align="center" rowspan="1" colspan="1">Stigmasterol</td><td align="center" rowspan="1" colspan="1">000083-48-7</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">43.</td><td align="center" rowspan="1" colspan="1">24.427</td><td align="center" rowspan="1" colspan="1">0.7673</td><td align="center" rowspan="1" colspan="1">1-hexacosanol</td><td align="center" rowspan="1" colspan="1">000506-52-5</td><td align="center" rowspan="1" colspan="1">91</td></tr><tr><td align="left" rowspan="1" colspan="1">44.</td><td align="center" rowspan="1" colspan="1">24.542</td><td align="center" rowspan="1" colspan="1">0.1545</td><td align="center" rowspan="1" colspan="1">Hexadecanoic acid, 2-hydroxy-,methyl ester</td><td align="center" rowspan="1" colspan="1">016742-51-1</td><td align="center" rowspan="1" colspan="1">59</td></tr><tr><td align="left" rowspan="1" colspan="1">45.</td><td align="center" rowspan="1" colspan="1">24.750</td><td align="center" rowspan="1" colspan="1">4.1775</td><td align="center" rowspan="1" colspan="1">
<italic>&#x003b3;</italic>-Sitosterol</td><td align="center" rowspan="1" colspan="1">000083-47-6</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">46.</td><td align="center" rowspan="1" colspan="1">24.843</td><td align="center" rowspan="1" colspan="1">0.8204</td><td align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>-Amyrone</td><td align="center" rowspan="1" colspan="1">000638-97-1</td><td align="center" rowspan="1" colspan="1">94</td></tr><tr><td align="left" rowspan="1" colspan="1">47.</td><td align="center" rowspan="1" colspan="1">25.241</td><td align="center" rowspan="1" colspan="1">0.8408</td><td align="center" rowspan="1" colspan="1">Lup-20(29)-en-3-one</td><td align="center" rowspan="1" colspan="1">001617-70-5</td><td align="center" rowspan="1" colspan="1">97</td></tr><tr><td align="left" rowspan="1" colspan="1">48.</td><td align="center" rowspan="1" colspan="1">25.443</td><td align="center" rowspan="1" colspan="1">1.2194</td><td align="center" rowspan="1" colspan="1">Lupeol</td><td align="center" rowspan="1" colspan="1">000545-47-1</td><td align="center" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">49.</td><td align="center" rowspan="1" colspan="1">25.559</td><td align="center" rowspan="1" colspan="1">0.0751</td><td align="center" rowspan="1" colspan="1">Benz[b]-1,4-oxazepine-4(5H)-thione, 2,3-dihydro-2,8-dimethyl-</td><td align="center" rowspan="1" colspan="1">1000258-63-4</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">50.</td><td align="center" rowspan="1" colspan="1">25.969</td><td align="center" rowspan="1" colspan="1">0.3833</td><td align="center" rowspan="1" colspan="1">Stigmast-4-en-3-one</td><td align="center" rowspan="1" colspan="1">001058-61-3</td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="left" rowspan="1" colspan="1">51.</td><td align="center" rowspan="1" colspan="1">26.431</td><td align="center" rowspan="1" colspan="1">0.0624</td><td align="center" rowspan="1" colspan="1">2,4-Cyclohexadien-1-one, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-</td><td align="center" rowspan="1" colspan="1">054965-43-4</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">52.</td><td align="center" rowspan="1" colspan="1">26.829</td><td align="center" rowspan="1" colspan="1">1.9166</td><td align="center" rowspan="1" colspan="1">Phytyl palmitate</td><td align="center" rowspan="1" colspan="1">1000413-67-8</td><td align="center" rowspan="1" colspan="1">96</td></tr><tr><td align="left" rowspan="1" colspan="1">53.</td><td align="center" rowspan="1" colspan="1">27.170</td><td align="center" rowspan="1" colspan="1">0.1216</td><td align="center" rowspan="1" colspan="1">1,4-Bis(trimethylsilyl)benzene</td><td align="center" rowspan="1" colspan="1">013183-70-5</td><td align="center" rowspan="1" colspan="1">78</td></tr><tr><td align="left" rowspan="1" colspan="1">54.</td><td align="center" rowspan="1" colspan="1">27.592</td><td align="center" rowspan="1" colspan="1">0.0250</td><td align="center" rowspan="1" colspan="1">2,4-Cyclohexadien-1-one, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-</td><td align="center" rowspan="1" colspan="1">054965-43-4</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">55.</td><td align="center" rowspan="1" colspan="1">28.463</td><td align="center" rowspan="1" colspan="1">0.3430</td><td align="center" rowspan="1" colspan="1">1,2-Bis(trimethylsilyl)benzene</td><td align="center" rowspan="1" colspan="1">017151-09-6</td><td align="center" rowspan="1" colspan="1">76</td></tr><tr><td align="left" rowspan="1" colspan="1">56.</td><td align="center" rowspan="1" colspan="1">29.376</td><td align="center" rowspan="1" colspan="1">0.9577</td><td align="center" rowspan="1" colspan="1">9,12-Octadecadienoic acid (Z,Z)-</td><td align="center" rowspan="1" colspan="1">000060-33-3</td><td align="center" rowspan="1" colspan="1">50</td></tr></tbody></table><table-wrap-foot><fn><p>Pk#: peak number; RT: retention time; Area%: percentage area covered; Library/ID Ref#: library/identification number; CAS#: chemical abstract scheme number.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>
<italic>In vitro</italic> DPPH scavenging activity (% inhibition) of 25-100&#x02009;<italic>&#x003bc;</italic>g/ml of <italic>IGESE</italic> and Vit. C.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Drug</th><th align="center" colspan="4" rowspan="1">Graded doses</th></tr><tr><th align="center" rowspan="1" colspan="1">25&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">50&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">75&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">100&#x02009;<italic>&#x003bc;</italic>g/ml</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>IGESE</italic>
</td><td align="center" rowspan="1" colspan="1">14.59 &#x000b1; 0.31</td><td align="center" rowspan="1" colspan="1">43.53 &#x000b1; 0.19</td><td align="center" rowspan="1" colspan="1">67.98 &#x000b1; 0.38<sup>b</sup></td><td align="center" rowspan="1" colspan="1">75.44 &#x000b1; 0.51<sup>c</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Vit. C</td><td align="center" rowspan="1" colspan="1">45.06 &#x000b1; 0.28</td><td align="center" rowspan="1" colspan="1">56.55 &#x000b1; 0.55<sup>a</sup></td><td align="center" rowspan="1" colspan="1">76.92 &#x000b1; 0.31<sup>c</sup></td><td align="center" rowspan="1" colspan="1">89.83 &#x000b1; 0.21<sup>c</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a, b,</sup> and <sup>c</sup> represent significant increases at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to the baseline value at 25&#x02009;<italic>&#x003bc;</italic>g/ml.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>
<italic>In vitro</italic> nitric oxide (NO) scavenging activity of 25-100&#x02009;<italic>&#x003bc;</italic>g/ml of <italic>IGESE</italic> and Vit. C.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Drug</th><th align="center" colspan="4" rowspan="1">Graded doses</th></tr><tr><th align="center" rowspan="1" colspan="1">25&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">50&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">75&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">100&#x02009;<italic>&#x003bc;</italic>g/ml</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>IGESE</italic>
</td><td align="center" rowspan="1" colspan="1">13.55 &#x000b1; 0.70</td><td align="center" rowspan="1" colspan="1">39.98 &#x000b1; 0.70</td><td align="center" rowspan="1" colspan="1">68.39 &#x000b1; 0.32<sup>b</sup></td><td align="center" rowspan="1" colspan="1">77.09 &#x000b1; 0.13<sup>c</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Vit. C</td><td align="center" rowspan="1" colspan="1">47.89 &#x000b1; 0.14</td><td align="center" rowspan="1" colspan="1">63.09 &#x000b1; 0.24<sup>b</sup></td><td align="center" rowspan="1" colspan="1">76.07 &#x000b1; 0.47<sup>c</sup></td><td align="center" rowspan="1" colspan="1">84.91 &#x000b1; 0.31<sup>c</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a, b,</sup> and <sup>c</sup> represent significant increases at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001, when compared to the baseline value at 25&#x02009;<italic>&#x003bc;</italic>g/ml.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>
<italic>In vitro</italic> FRAP activities of 25-100&#x02009;<italic>&#x003bc;</italic>g/ml of <italic>IGESE</italic> and Vit. C.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Drug</th><th align="center" colspan="4" rowspan="1">Graded doses</th></tr><tr><th align="center" rowspan="1" colspan="1">25&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">50&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">75&#x02009;<italic>&#x003bc;</italic>g/ml</th><th align="center" rowspan="1" colspan="1">100&#x02009;<italic>&#x003bc;</italic>g/ml</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>IGESE</italic>
</td><td align="center" rowspan="1" colspan="1">0.08 &#x000b1; 0.00</td><td align="center" rowspan="1" colspan="1">0.13 &#x000b1; 0.04<sup>a</sup></td><td align="center" rowspan="1" colspan="1">0.28 &#x000b1; 0.00<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.48 &#x000b1; 0.00<sup>c</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Vit. C</td><td align="center" rowspan="1" colspan="1">0.24 &#x000b1; 0.00</td><td align="center" rowspan="1" colspan="1">0.38 &#x000b1; 0.00<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.48 &#x000b1; 0.00<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.63 &#x000b1; 0.00<sup>c</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a, b,</sup> and <sup>c</sup> represent significant increases at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to the baseline value at 25&#x02009;<italic>&#x003bc;</italic>g/ml.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Antioxidant enzyme activities of 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> in DOX-treated rat cardiac tissue.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Groups</th><th align="center" colspan="6" rowspan="1">Antioxidant parameters</th></tr><tr><th align="center" rowspan="1" colspan="1">GSH</th><th align="center" rowspan="1" colspan="1">GST</th><th align="center" rowspan="1" colspan="1">GPx</th><th align="center" rowspan="1" colspan="1">SOD</th><th align="center" rowspan="1" colspan="1">CAT</th><th align="center" rowspan="1" colspan="1">MDA</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">18.8 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">9.5 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">43.6 &#x000b1; 4.7</td><td align="center" rowspan="1" colspan="1">4.3 &#x000b1; 0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">20.4 &#x000b1; 0.6</td><td align="center" rowspan="1" colspan="1">2.7 &#x000b1; 0.2<sup>b+</sup></td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">10.4 &#x000b1; 1.2</td><td align="center" rowspan="1" colspan="1">62.7 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">6.0 &#x000b1; 0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">14.8 &#x000b1; 0.8<sup>b&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1; 0.2<sup>a&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">1.0 &#x000b1; 0.1<sup>a&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">6.9 &#x000b1; 0.6<sup>b&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">16.7 &#x000b1; 2.3<sup>c&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">12.8 &#x000b1; 1.0<sup>c+</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">21.3 &#x000b1; 1.3<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1; 0.3<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 0.2<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">11.5 &#x000b1; 1.5<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">51.4 &#x000b1; 5.2<sup>d+,d</sup></td><td align="center" rowspan="1" colspan="1">5.2 &#x000b1; 0.5<sup>e&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">17.0 &#x000b1; 1.4<sup>d</sup></td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 0.2<sup>d</sup></td><td align="center" rowspan="1" colspan="1">1.3 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">11.1 &#x000b1; 1.5<sup>d+,d</sup></td><td align="center" rowspan="1" colspan="1">54.2 &#x000b1; 6.5<sup>d+,d</sup></td><td align="center" rowspan="1" colspan="1">5.3 &#x000b1; 0.6<sup>e&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VI</td><td align="center" rowspan="1" colspan="1">19.6 &#x000b1; 1.8<sup>d+,d</sup></td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 0.1<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">2.3 &#x000b1; 0.3<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">12.8 &#x000b1; 1.4<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">56.6 &#x000b1; 4.3<sup>d+,d</sup></td><td align="center" rowspan="1" colspan="1">3.9 &#x000b1; 0.4<sup>f&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VII</td><td align="center" rowspan="1" colspan="1">24.7 &#x000b1; 1.3<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">3.0 &#x000b1; 0.4<sup>f+,f</sup></td><td align="center" rowspan="1" colspan="1">3.3 &#x000b1; 0.4<sup>f+,f</sup></td><td align="center" rowspan="1" colspan="1">15.4 &#x000b1; 1.6<sup>e+,e</sup></td><td align="center" rowspan="1" colspan="1">78.7 &#x000b1; 6.9<sup>f+,f</sup></td><td align="center" rowspan="1" colspan="1">3.5 &#x000b1; 0.4<sup>f&#x02212;</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>b+</sup> represents a significant increase at <italic>p</italic> &#x0003c; 0.001 when compared to untreated negative (normal) control (Group I) values; <sup>c+</sup> represents a significant increase at <italic>p</italic> &#x0003c; 0.0001 when compared to <italic>IGESE</italic>-only treated (Group II) values; <sup>a-,b-,</sup> and<sup>c-</sup> represent significant decreases at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to Groups I values; <sup>d+</sup> and <sup>e+</sup> represent significant increases at <italic>p</italic> &#x0003c; 0.001 and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to untreated positive control (DOX-only treated, Group III) values; while <sup>e-</sup> and <sup>f-</sup> represent significant decreases at <italic>p</italic> &#x0003c; 0.001 and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to untreated positive control (DOX-treated only, Group III) values, respectively. <sup>d, e,</sup> and <sup>f</sup> represent significant increases at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to untreated positive control (DOX-treated only, Group III).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab8" orientation="portrait" position="float"><label>Table 8</label><caption><p>Effect of 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> on serum LDH and cardiac troponin I (cTnI) levels in DOX-intoxicated rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Treatment groups</th><th align="center" rowspan="1" colspan="1">LDH (U/L)</th><th align="center" rowspan="1" colspan="1">cTnI (ng/ml)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">4347 &#x000b1; 596.4</td><td align="center" rowspan="1" colspan="1">3.4 &#x000b1; 1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">4338 &#x000b1; 238.1</td><td align="center" rowspan="1" colspan="1">3.7 &#x000b1; 1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">8151 &#x000b1; 441.0<sup>c+</sup></td><td align="center" rowspan="1" colspan="1">40.5 &#x000b1; 3.5<sup>c+</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">4887 &#x000b1; 217.5<sup>a&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">11.4 &#x000b1; 3.5<sup>c&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">4737 &#x000b1; 260.2<sup>a&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">25.5 &#x000b1; 3.3<sup>a&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VI</td><td align="center" rowspan="1" colspan="1">4188 &#x000b1; 229.2<sup>b&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">19.8 &#x000b1; 2.4<sup>b&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VII</td><td align="center" rowspan="1" colspan="1">3679 &#x000b1; 346.1<sup>c&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">14.8 &#x000b1; 1.1<sup>c&#x02212;</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>c+</sup> represents a significant increase at <italic>p</italic> &#x0003c; 0.0001 when compared to untreated normal control (Group I) and <italic>IGESE</italic> only treated (Group II) values, while <sup>a-, b-</sup> and <sup>c-</sup> represent significant decreases at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to DOX-only treated (Group III) values, respectively.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab9" orientation="portrait" position="float"><label>Table 9</label><caption><p>Effect of 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> on complete serum lipid profile.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Groups</th><th align="center" colspan="4" rowspan="1">Serum lipids</th></tr><tr><th align="center" rowspan="1" colspan="1">TG(mmol/l)</th><th align="center" rowspan="1" colspan="1">TC(mmol/l)</th><th align="center" rowspan="1" colspan="1">HDL-c(mmol/l)</th><th align="center" rowspan="1" colspan="1">LDL-c(mmol/l)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.7 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">0.7 &#x000b1; 0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">1.8 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.6 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">0.6 &#x000b1; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1; 0.1<sup>a&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">2.7 &#x000b1; 0.3<sup>c+</sup></td><td align="center" rowspan="1" colspan="1">0.7 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1; 0.2<sup>c+</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.1<sup>d+</sup></td><td align="center" rowspan="1" colspan="1">1.4 &#x000b1; 0.2<sup>f&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">0.8 &#x000b1; 0.1<sup>a+</sup></td><td align="center" rowspan="1" colspan="1">0.4 &#x000b1; 0.2<sup>f&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">1.0 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 0.2<sup>d&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">0.8 &#x000b1; 0.1<sup>a+</sup></td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.1<sup>d&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VI</td><td align="center" rowspan="1" colspan="1">1.3 &#x000b1; 0.2<sup>d+</sup></td><td align="center" rowspan="1" colspan="1">2.3 &#x000b1; 0.2<sup>d&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1; 0.1<sup>b+</sup></td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1; 0.2<sup>d&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VII</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1; 0.0<sup>e+</sup></td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1; 0.1<sup>f&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">0.6 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">0.6 &#x000b1; 0.1<sup>f&#x02212;</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a-</sup> represents a significant decrease at <italic>p</italic> &#x0003c; 0.05 when compared to (Groups I and II) values, while <sup>c+</sup> represents a significant increase at <italic>p</italic> &#x0003c; 0.0001 when compared to Groups I and II values; <sup>d-</sup> and <sup>f-</sup> represent significant decreases at <italic>p</italic> &#x0003c; 0.05 and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to DOX-only treated (Group III) values; <sup>d+</sup> and <sup>e+</sup> represent significant increases at <italic>p</italic> &#x0003c; 0.05 and <italic>p</italic> &#x0003c; 0.001, respectively, when compared to DOX-only treated (Group III) values.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab10" orientation="portrait" position="float"><label>Table 10</label><caption><p>Effect of 100-400&#x02009;mg/kg/day of <italic>IGESE</italic> on cardiovascular risk indices (atherogenic index (AI) and coronary risk index (CRI)) values in DOX-intoxicated rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Treatment groups</th><th align="center" rowspan="1" colspan="1">TC &#x000f7; HDL &#x02212; c&#x02009;(AI)</th><th align="center" rowspan="1" colspan="1">LDL &#x02212; c &#x000f7; HDL &#x02212; c&#x02009;(CRI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">2.83 &#x000b1; 0.05</td><td align="center" rowspan="1" colspan="1">1.05 &#x000b1; 0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">2.86 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">1.11 &#x000b1; 0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">3.85 &#x000b1; 0.19<sup>b+</sup></td><td align="center" rowspan="1" colspan="1">2.28 &#x000b1; 0.20<sup>c+</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">1.88 &#x000b1; 0.39<sup>a&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">0.64 &#x000b1; 0.33<sup>c&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">3.10 &#x000b1; 0.23<sup>a&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">1.51 &#x000b1; 0.16<sup>a&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VI</td><td align="center" rowspan="1" colspan="1">2.56 &#x000b1; 0.27<sup>b&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">1.30 &#x000b1; 0.27<sup>b&#x02212;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">VII</td><td align="center" rowspan="1" colspan="1">2.62 &#x000b1; 0.18<sup>b&#x02212;</sup></td><td align="center" rowspan="1" colspan="1">0.98 &#x000b1; 0.16<sup>c&#x02212;</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>b+</sup> and <sup>c+</sup> represent significant increases at <italic>p</italic> &#x0003c; 0.001 and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to Groups I and II values, respectively, while <sup>a-, b-,</sup> and <sup>c-</sup> represent significant decreases at <italic>p</italic> &#x0003c; 0.05, <italic>p</italic> &#x0003c; 0.001, and <italic>p</italic> &#x0003c; 0.0001, respectively, when compared to untreated positive control (DOX-only treated) (Group III) values, respectively.</p></fn></table-wrap-foot></table-wrap></floats-group></article>